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Propofol is a commercially available intravenous 
anaesthetic agent. The main feature of propofol is rapid 
recovery from anaesthesia, whether given as a bolus for 
induction of anaesthesia or by , infusion to maintain 
anaesthesia. 
The aim of this thesis was to develop analytical 
techniques for measuring the conqentration of propofol. It 
details the assay of propofol in blood samples using high-
pressure liquid chromatography (HPLC) with fluorescence 
detection, and propofol protein binding studies using 
eq~ilibrium dialysis. Examples are given of clinical 
applicati~ns of these techniques. 
The reversed phase HPLC method used was simple, 
sensitive, and reliable. The assay involved a single 
extraction of the drug and internal standard, thymol, from 
blood buffered with 0.1 M sodium dihydrogen phosphate 
buffer into cyclohexane. The organic extract, basified with 
tetramethylammonium hydroxide, was evaporated to dryness at 
37°C under nitrogen. The residue was redissolved in 80 ~l 
acetonitrile and an aliquot of the concentrate was injected 
into a C18 reversed-phase column. The mobile phase 
" 
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consisted of 66% (v/v) acet6nitrile in Milli-Q water 
containing 1% v/v acetic acid and was eluted at 1.7 ml/min. 
The components of the column effluent was monitored by a 
fluorometric detector with excitation and emission 
wavelengths set at 276 nm and 310 nm, respectively. The 
main advantage of my method for detecting propofol is that 
only 0.5 ml of whole blood is required. This facilitates 
pharmacokinetic studies of propofol in children. The 
calibration graphs were linear over the range 2-3000 ng/ml 
with coefficients of variation ranging from 0.38 to 7.86%, 
while the limit of detection was approximately 2 ng/ml. The 
intraassay coefficient of variation of propafol in whole 
blood was 6.24% at 100 ng/ml and 6.10% at 500 ng/ml, while 
the interassay coefficient of variation was 3.18% at 100 
ng/ml and 1.81% at 500 ng/ml. The extraction recovery 
results obtained for propafol in whole blood are 104% at 
100 ng /ml and 99% at 500 ng/ml. Stability of propofol in 
whole blood is one month. The results of propofol assay in 
plasma are similar to propofol assay in whole blood. 
For the protein binding assay, equilibrium dialysis 
was performed using a Spectrum equilibrium Dialyser. Drug-
containing plasma samples or protein solutions (1 ml) were 
dialysed against drug-free Sorensen's phosphate buffer (1 
ml; pH 7.4) in teflon dialysis chambers separated by 
Spectra/Por dialysis membrane. The effect of drug 
concentration on protein binding was determined within the 
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range of 0.25-3.00 p,g/ml of propofol. The teflon cells 
rotate at 15 rpm at 37°C. The' optimum dialysis time was 240 
min. Propofol concentration in samples were assayed by HPLC 
as described above. The intraassay coefficient of variation 
of propofol protein binding was 0.11% (3.65% Free), while 
the interassay coefficient of variation of propofol protein 
binding was o. 23% ( 8 . 57% Free). The extraction recovery 
results obtained for propofol in plasma are 96.42% in 
unheated samples, 90.64% for samples heated at 37°C, and 
97.15% samples dialysed at 37°C in a water-bath. 
One application of my research was the prospective 
testing in chinese children of a previously published 
pharmacokinetic model driven algorithm for computer 
controlled infusion of propofol. The model was revised 
using an iterative linear least squares regression and 
minimizing total mean squared prediction error for each 
patient. The precision of the revised model was 21.08% and 
bias was 0.19%. 
Another application of my research was to investigate 
protein binding of propofol in different populations 
be9ause pharmacological response to drugs is influenced by 
the free fraction of drug. There were no differences in 
~rot~in binding between young children [< 3 years, 98.77 ± 
0.29% ~mean ± S.D.)], children (3-12 years, 98.69 ± 0.33%) 
and . adults (98.35 ± 0.29%). 
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Pregnant patients had increased free propofol, 1.41 ± 
0.30% compared with nonpregnant patients, 1.08 ± 0.26% (p 
=0.004). Free propofol in umbilical plasma 3.40 ± 0.61% was 
greater than that in maternal (pregnant) plasma (p= 
0.001). These findings indicate that further simultaneous 
pharmacodynamic/pharmacokinetic studies would be useful to 
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Propofol (2,6-diisopropyl phenol) is an intravenous 
anaesthetic agent which is metabolized rapidly. " After 
anaesthesia with propofol, patient recovery is typically 
rapid and clear headed. Although the main role of propofol 
was initially that of "a drug to ~e given as a bolus for 
induction of anaesthesia, the large total body clearance of 
propofol also '"made it suitable for administration by 
infusion for the maintenanc~ of anaesthesia. The perceived 
clinical advantages of intravenous anaesthesia with 
propofol has led to a rapid expansion in both the patient 
groups in which piopofol is being used and the anaesthetic 
techniques for delivering propofol. 
Rational and appropriate dosing regimens for a drug 
are calculated from the known pharmacokinetics "of that 
drug. The pharmacokinetics of propofol, as for any drug, 
were · first determined in healthy adults. However this 
information may not be applicable to different patient 
groups 'such as the obstetric, neonatal and paediatric 
popu~ations. Researchers in the De~artment of Anae~thesia 
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and Intensive Care at the Prince of Wales Hospital, Chinese 
University of Hong Kong, were interested in studying 
anaesthesia with propofol in obstetric and paedlatric 
patients but two potential problems were forseen in 
determining the pharmacokinetics of propofol in these 
groups. 
Firstly, blood sampling in the paediatric population 
is difficult and limited ethically by the volume of blood 
which may be removed. ' Thus a method must be established for 
determining propofol concentrations accurately with as 
small a blood volume as is practical. It was thought that 
existing method~ for the assay of propofol could be further 
developed and refined. 
Secondly, propofol was known to be highly bound to 
plasma proteins and red blood cells. Although it is 
accepted generally that only the ' unbound drug is free to 
cross cell membranes, be distributed, exert an effect and 
be metabolized, there was little detailed information on 
the protein binding of propofol. Such data could be 
important in the obstetric, neonatal and pa~diatri~ patient 
groups because they have significant alterations in protein 
,and blood composition compared with normal healthy adults. 
This thesis reports the development of two analytical 
method,s for measuring propofol: a sensitive assay of total 
24 
blood propofol using small blood volumes and a method for 
determining the bound and unb6und fraction of propofol in 
blood. A summary of the pharmacology of propofol and some 
examples of the clinical application of these two 




THE PHARMACOLOGY OF PROPOFOL 
The commercial preparation 'Diprivan' (Zeneca 
Pharmaceuticals) is a white, isotonic oil-in-water emulsion 
for intravenous injection containing 10 mg propofol per ml. 
The vehicle coptains a l%w Iv solution in an aqueous 
emulsion of 10% 'soya bean oil, · 2.25% glycerol, 1.2% 
purified egg· phosphatide ~nd sodium hydroxide. 
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1: Chemistry, structure-Activity relationship 
OH 
l ~----------------------------~------------------------------~ 
. . \ 
Fiq ~ 2-1: structural formula af prepafel 
Pr opofol (2/6~diisopropylphenol: Fig. 2-1:) represents 
a new class of intravenous anaesthetic agent, chemically 
unrelated to barbiturate, steroid or eugenol agents. It is 
one of a series of sterically hindered phenols that exhibit 
anaesthetic activity (James et aI, 1980). It has a 
molecular we ight of 178 da ltons and i s a colour l ess liquid 
at room temperature. 
T~e compound absorbs in the ultraviolet .range of the 
. electrom~gnetic spectrum (A max275 nm) and fluoresces at 
310 nm with an excitation wavelength of 276 
nm . 
. Fluorescence detection with high pressure liquid 
27 
·f '· 
chromatography forms 'the basis of the standard blood 
concentration assay technique (Plummer 1987). 
Substitution at the ortho position of the parent compound, 
phenol, induces steric hindrance in the adjacent hydroxyl ' 
group, modifying the hydrogen bond donor-acceptor 
properties. This structural change in turn attenuates the 
protein denaturing effect and confers anaesthetic activity 
(James et al. 1980). optimal anaesthetic activity is 
obtained ' by sUbstitution at the 2 and 6 positions with 
secondary alkyl groups so that there are a total of' six to 
eight carbon atoms in the sUbstituent chains. Increasing 
the number of carbon atoms beyond eight leads to a slower 
induction time, prolonged recovery time, and ultimately 
loss of anaesthetio action. 
2: Pharmacokinetics 
The pharmacokinetics of propofol have been evaluated 
in surgical patients receiving ' single or repeat bolus 
doses, and also continuous infusions. Propofol undergoes 
rapid and ext~nsive distribution, and rapid metabolic 
clearance. Due to high lipophilicity and extensive tissue 
binding, . the volumes of distribution are very high and the 
. steady state and elimination phase volumes of distribution 
exceed total body water. 
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2.1: Distribution 
Blood concentration-time curves obtained following 
single bolus injections show that propofol very rapidly 
distributes from the circulation into tissues. Estimations 
of-" the distribution half-life (tl/2a ) have varied from 1.8 to 
4.7 minutes. Autoradiographic studies in rats demonstrated 
that propofol appears in the brain within 30 seconds of 
intravenous administration (Rhodes & LongshaW1977). 
Pharmacokinetic modelling of human data in4icated a mean 
blood-brain equilibration half-time of 2.9 minutes 
(Schuttler et al. 1988), which <?oncurs with propofol's 
rapid onset of action. The apparent volumes of distribution 
of propofol in the central compartment (Vc), at steady-state 
(V~) and during the elimination phase (~) are high (13 to 
76 L, 171 to 349 Land 209 to 1008 L), reflecting extensive 
tissue . distribution 
" 
of propofol related to high 
lipophilicity (Cockshott 1985). 
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2.2: Elimination 
When a subanaesthetic dose of 14C-labelled propofol was 
given intravenously to 6 male volunteers (mean dose 0.47 
mg/kg), 88% of the administered radioactivity was recovered 
" 
in the urine, whilst less than 2% was excreted in the 












Fig. 2-2:' The metabolism and urinary excretion of 
propofol (after simons et at. 1988) 
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Analysis of the radioactive material excreted in urine 
revealed that less than 0.3% was unchanged propofol, whilst 
approximately 40% was propofol glucuronide and the 
remainder consisted of the 1-and 4-glucouronide and 4-
sulphate conjugates of 2,6-diisopropyl l,4-quinol (Fig. '2-
2: . The metablolism and urinary excretion of propofol). 
Metabolism of propofol is rapid; in the above study. un-
changed propofol accounted for 94% of the radioactive 
material in blood 2 minutes after injection, but after 30 
. minutes 81% of the radioactivity was in -the form of 
metabolites. The total clearance of propofol given either 
as a bolus inj~ction or as an · infusion to patients 
receiying no other anaesthet.ic agent was between 94 and 139 
L/h. A similar range was observed when supplementary 
anaesthetics . were given (108 to 136 L/h). Since normal 
hepatic blood flow in man has been estimated to b'e between 
66 and 108 L/h (George 1979), these clearance values for 
propofol suggest that s6me extrahepatic metabolism occurs 
(Cockshott 1985), particularly as hepatic blood flow is 
reduced in anaesthetized patients (Nies et al. 1976) . 
. , The pharmacokinetics of propofol have been described · 
usirig both open 2-compartment (Schlittler et al ~ . 1985; 
Simons ~t al. 1988) and open 3-compartment mOdels 
. (Cockshott et al. 1987; Gepts et al. 1987; Kay et al. 
. .. 
1986). In those studies, the concentration time data are 
best fitted by a 3-compartment model. The tl~ of 1.8-4.1 
. minutes is attributed to distribution from . blood: into 
31 
tissues; a t 1np of 25-56 minutes represents metabolic 
clearance from blood; whilst the terminal elimination ph~se 
occurred more slowly with a half-life(tl~) of 184 t6 309 
minutes fqllowing single bolus injections, and of 277 to 
403 minutes . following · continuous infusions (Table 2-1: 
Pharmacokinetic data for propofol obtained surgical 
patients). since this terminal elimination phase is 
probably a consequence of the slow return of propofol from 
a poorly perfused compartment, this apparent increase in tl~ 
following continuous infusion may be due to adbumulation of 
~ 
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Fig 2-3: Meari blood propofol concentration in 6 female 
patients with normal hepatic and renal function following 
indUction doses of propofol 2. 5 mgjkg (after Cockshott 
1985) • 
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2.3: Effects of age, sex, and hepatic and renal disease 
on the pharmacokinetics of propofol 
2.3.1: Effects of age 
The reduction in clearance suggests that metabolism of 
propofol is reduced in the elderly, possibly as a result of 
the reduction in hepatic blood flow that occurs with age. 
Blood concentrations of propofol at 2 minutes after 
injection-were significantly higher in the elderly patients 
(6:1 vs 4.2 mg/Li p < 0.02). This is partly a ;esult of the 
decrease in Vc (The central volume of distribution) in these 
patients and probably explains why. the elderly are more 
sensitive to propofol (Dundee et at. 1986) . The 
pharmacokinetics "of propofol were obtained for 12 elderly 
patients (65 to 80 years) . who received single bolus 
injection of propofol 2 mg/kg and were compared with those 
obtained from a control group of 12 younger patients (18 to 
35 years) who received doses of 2.5 mg/kg. In both groups 
papaveretum (10 to 20 mg intramuscularly) was given 1 hour 
before surgery and anaesthesia was maintained with up to 1 
. % halothane/67% : nitrous oxide in oxygen. - For both study 
groups the data were fitted to an open 3-compartmentmodel. 
The terminal elimination half-life was similar for both the 
elderly (834 minutes) and younger patients (674 minutes), 
but ·· propofol clearance was significantly reduced in the 
elderly 8 6 v~ 107 L/h i P < O. 05). The initial volume of 
dIstribution (Vc) was significantly reduced in the e~_derly 
35 
(19.6 vs 26.3 L; P < 0. ,05) (Kirkpatrick et al. 1988). 
2.3~2: Effects of Sex 
Kay and associates (1986) compared the 
pharmacokinetics of propofol in male and female surgical 
patients and found no significant differences in clearance, 
volumes of distribution and distribution and elimination 
half-lives. The ratio of volume of distribution at steady-
state (Vss) to volume of distribution during elimination (Vd) 
was relatively low in these patients (0.58 or ~ less), again 
probably as a result of retention of propofoi in poorly 
, perfused fat deposits,but it was s,ignificantly higher in 
men than in women (p = 0.021; Kay et at. 1986). 
" 
2.3.3: Effects of renal and hepatic disease 
Mean distribution and elimination half-lives were 
measured in ~ patients with renal insufficiency who were 
undergoing abdominal surgery and were found to be slightly 
lower than in a similar group of 6 patients with normal 
renal function, but the differences were not statistically 
significant. In addition, total propofol clearance values 
were simila~ in the 2 groups (renal insufficiency, 111 L/h; 
normal renal function, 100 L/h) (Morcos & Payne 1985), and 
on the basis of these limited findings it would seem that 
renal ' disease does .not seriously alter propofol 
pharmacokinetics. 
The liver is the most important site of e~imination, 
36 
and very high clearance values, of 70-140 L/hr have been 
reported (Sebel et al. 1989). The pharmacokinetics of an 
induction dose of propofol 2.5 mg/kg .in 10 patients with 
uncomplicated liver cirrhosis were compared with a group 
- -
of 10 patients with normal liver function. No significant 
pharmacokinetic differences were found between the groups, 
and the authors suggested that extrahepatic metabolism of 
propafol may compensate for reduced liver function (Servin 
et al. 1988). Servin and cpworkers (1990) have compared the 
pharmacokinetics of propofol as an infusion in 10 control 
and 10 patients with cirrhosis. Total body clearance was 
not :reduced significantly in cirrhotic (1.56 ± 0.48 L/min) 
compared with control (1.75 ± 0.32 L/min) patients. The 
, 
volume of distribution at steady state was significantly 
greater in patients with cirrhosis than in control patients 
(202 ± 82 L vs 121 ± 49 L). However, this difference did 
not significantly change terminal elimination half-life. 
The pharmacokinetics of propofol -given by infusion to 
maintain general anaesthesia were not affected markedly by 
moderate cirrhosis. 
37 
3: ' Pharmacodynamic 
3.1: Anaesthetic concentrations 
studies desfgned to determine the minimum infusion 
" 
rate of propofol needed to suppress the initial response to 
surgical incision provide data on blood concentration 
requirements for anaesthesia. Fifty-seven patients, 
premedicated with morphine 0.15 mg/kg, had anaesthesia 
induced with 2 mg/kg of propofol, supplemented by 67 % 
nitrous oxide in oxygen (Spelina et al. 198'6). When a 
' propofol infusion had been in progre~s for at least 30 
minutes, at which time blood concentrations approximated to 
I 
steady state cond'itions (Coates et al. 1987), the response 
to the initial surgical stimulus was noted. The mean whole 
blood propofol concentrations required to suppress movement 
in" 50 % and ~5 % of patient (EDso and ED9S ) were 1.67 p.g/ml 
and 3.38 p.g/ml, respectively. Higher concentrations (ED~ 
2 • 5 p.g /ml ; ED95 5 • 92 p.g /ml) were required to suppress 
movement at incision following a benzodiazepine 
premedication (Turtle et al. 1987). 
Following administration of single bolus doses or 
after stopping infusions ,of propofol, patients wake at a 
mean blood propofol concentration of approximately 1.0 
p.glml . . , 'Waking occurred about 10 minutes after a single 
bolus dose of 200 mg at a mean blood propofol concentration 
of 1.1 p.g/ml (range 1.0 to 2.19 p.g/ml) in the absence of 
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other drugs (Schlittler et aI, 1985). Propofol was 
administered asa bolus dose, 2 mgjkg intravenous, followed 
by a ~ariable-rate infusion, 0~20 mgjmin, and intermitt~nt 
supplemental boluses, 10-20 mg intravenous. Blood pro~ofol 
concentrations at which 50 % of patients (EC50) were awake 
and -oriented after surgery were 1.07 and 0.95 ~gjml (Shafer 
et aI, 1988). 
3.2: Recovery characteristics 
The need to make more eff ic:ient . use of hospital 
resources has led to an increasing number of minor surgical 
.procedures being "carried out on an out-patient basis. In 
such circumstances an important requirement is that 
recovery from anaesthesia should be rapid with minimal 
residual eff~ct. The wealth of favourable data generated 
from clinical studies has encouraged widespread use of 
propofol in this field. A number of studies have compared 
methohexitone with propofol for induction and maintenance, 
" 
or for induction" only followed by inhalation anaesthesia. 
Immediate recovery times were either equivalent for the two 
drugs or were shorter after propofol, with the exception of 
one study where single bolus injections were· used to 
facilitate dental extractions (Logan et al. 1987) 
Although recovery from anaesthesia ' with either 
propof9l or methohexitone was sufficient to allow patients 
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to be sent home on the same day as surgery was performed, 
psychomotor performance tests showed that functional 
impairment was less prolonged after propofol. Walking 
abi I i ty and correct balance also returned more quickly 
after propofol anaesthesia, whilst nausea and vomiting were 
more frequent in the patients who received methohexitone. 
Overall assessments of anaesthesia and recovery generally 
found propofol to be the s~perior drug. Results from take-
home questionnaires which were used in one study indicated 
that patients generally felt better after propofol 
.-
anaesthesia and that this difference persisted after 
discharge (Kay & Healy 1985). Isoflurane has been compared 
with propofol for the maintenance of anaesthesia following 
induction with propofol in outpatient surgical procedures. 
Again I al though both provided adequate anaesthes ia and 
rapid recovery, psychomotor performance improved more 
rapid l y after main t enance wi th propofo l (Mi 11 i gan e t a l . 
1987). 
3.3: Effects on the cardiovascular system 
Propofol causes a significant fall in arterial blood 
pressure and total peripheral resistance, with a slight 
fall in cardiac output. The heart rate may increase. 
McCollum and Dundee (1986) compared the effects of propofol 
2-2.5 mg/kg, thiopental 4-5 mg/kg, methothexital 1.5 mg/kg, 
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and etomidate 0.3 mg/kg, given over 20 seconds to 
unpremedicated patients. Administration of 2.5 mg/kg 
propofol produced the greatest mean decrease in systolic 
blood pressure (-17 %) at 2 minutes, being significantly 
greater than that produced by 5 mg/kg thiopental. Grounds 
et al. (1985) reported that the 32 % fall in mean blood 
pressure observed 2 minutes after induction of anaesthesia 
with 2 mg/kg propofol resulted from a 13 % decrease in 
cardiac output and a 21 fall in systemic vascular 
resistance, wi th minimal changes in heart rate. These 
changes were not significantly greater than those produced 
by thiopental 4 mg/kg. 
Coates et al. (1987) used an induction dose of 2 
mg/kg, followed ~y a continuous infusion of 3.24 mg/kg/h to 
supplement anaesthesia, with 67 % nitrous oxide in oxygen 
for body surface surgery and reported similar hemodynamic 
alterations. There were no further significant changes in 
systolic or ~iastolic blood pressure during the infusion, 
but cardiac output decreased to 65 % of the awake value . 
The introduction of positive pressure ventilation was 
associated with a significant increase in systemic vascular 
resi·stance compared with the value for spontaneously 
breathing patients, but no other hemodynamic indices showed 
any significant varia tion . 
Twenty patients were divided randomly for 
administration of 2 mg/kg propofol (group Propofol, n = 10) 
or 0.9% saline solution (group Control, n = 10) during 
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cardiopulmonary bypass (CPB) . The two groups were 
comparable with respect to sex, age, height, type of 
surgery (valvular or cor9nary), arterial hypertension and 
preoperative antihypertensive treatment. Mean arterial 
pressure (MAP), systemic vascular resistance (SVR) and SVR 
index were significantly lower in the propofol group than 
in the control group at 10, 15 and 20 min of study, 
suggesting that the hypotensive effect of a bolus injection 
of propofol is due, at least in part, to a direct decrease 
in the SVR (Pensado et aI, 1993). 
The effects on corrected QT interval (QTc) , heart rate 
. and arterial pressure were studied. after induction with 
propofol 1.5, 2 or 2 . 5 mg /kg , thiopentone 5 mg /kg or 
.' 
methohexitone 2 mg/kg in 123 ASA class I or II children 
undergoing outpatient otolaryngological surgery. After 
injection of the intravenous anaesthetic, the QTc interval 
was signific~ntly prolonged after propofol 2.5 mg/kg. 
Thirty seconds after suxamethonium 1.5 mg/kg, a significant 
prolongation of the QTc interval occurred in the 
thiopentone and propofol 1. 5 and 2 mg /kg groups. After 
intubation, no further prolongation of the QTc interval 
occurred in any of the groups. Heart rate increased 
significantly after the barbiturates but not after 
propofol. Systolic arterial pressure decreased 
sign~f~cantly after propofol 1.5 and 2.5 mg/kg. In all 
groups a ' cardiovascular intubation response occurred. 
Bradycardia and junctional rhythm occurred in 4% of the 
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children in both barbiturate groups and in 19-29% in the 
propofol groups. It is concluded that propofol causes 
prolongation of the QT interval and results in a higher 
incidence of bradycardia and junctional rhythm than the 
barbiturates (Saarnivaara et al, 1993). 
3.4: Effects on the respiratory system 
Propofol is a respiratory depressant. A bolus dose of 
propofol may cause a decrease in tidal volume, leading to 
apnoea in many patients . This has been a consistent 
observation in clinical studies where propofol has been 
used to induce ~naesthesia, and although the duration of 
apnoea is usually short (60 seconds or less) it may persist 
for up to 3 minutes (Goodman et al. 1987). Similarly, the 
incidence of apno~a varies considerably, occurring in 
between 50 and 84% of patients and this may be dependent 
upon a variety of factors, such as premedication, speed of 
administration, dose, hyperventilation and hypercapnia. 
Detailed respiratory measurements in 16 unpremedicated 
surgical patients who received an induction dose of 
propofol 2.5 mg/kg revealed that the apnoea was preceded by 
a rapid reduction in tidal volume (usually accompanied by 
tachypnoea) which was maximal about 30 seconds after 
injection and then progressed into full apnoea. Breathing 
then resumed spontaneously with small tidal volumes which 
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increased over a period of about 1 minute to a steady rate 
(Goodman et al. 1987). 
Both vt and Vi were decreased during infusion at 6 
mg/kg/h and showed a further reduction when the infusion 
rate was doubled, whilst the respiratory frequency 
increased .to a maximum during the postinduction period then 
decreased slightly during the constant infusion. The 
inspiratory duty cycle (~/T~ - the ratio of inspiratory 
time to total ventilatory cycle time) was reduced · during 
the lower rate infusion and further decreased when the rate 
was increased. In addition I analysis of the ventilatory 
response to rebreathed carbon dioxide in 8 of the patients 
indicated that an infus ion of propofol 6 mg / kg/ h r educed 
.. 
t his response ( dete~mined as t he gradient of the carbon 
dioiide rebreathing curve) to an average of 58 %, within 
95% confidence limits of 32 and 84 %. (Goodman et al. 1987). 
3.5: Effects on cerebral blood flow and intracranial 
pressure 
. In patients without intracranial pathology, prepofol 
decreases cerebral blood flow (CBF) by 26% (Vandesteene et 
al. 1988) to 51% (Stephan et al. 1987), and increases 
cerebro~ascular resistance (CVR) by 51% to 55%. Propofol 
was found - to decrease cerebral metabolic requirement for 
oxygen .to a significant degree (36%) in one stuqy (Stephan 
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et al. 1987), but insignificantly (18%) in another study 
(Vandesteene et al. 1988), which combined a propofol 
infusion with nitrous oxide (65%), oxygen, and enflurane 
(0.5%). The reactivity of the cerebral vessels to changes 
in Pco2 seems to be maintained during anaesthesia with 
propofol. The effects of propofol in patients with elevated 
intracranial pressure (ICP) have been studied with propofol 
(2~mg/kg) administered to six comatose patients with ICP 
greater than 25 mmHg. In this group of patient, ICP 
decreased significantly. However, the cerebr~~ perfusion 
pressure (CCP) also decreased in four of six patients below 
-the minimum safe CCP of 50 mmHg due to a decrease in 
arterial pressure (Herregods et al. 1988). 
3.6: Other effects 
3.6.1: Effects on liver function 
Propofol has minimal adverse effects on liver ' 
function, as evidenced by the absence of change in liver 
function tests 'such as aspartate transaminase (AST) , 
alanine transaminase (ALT) , or alkaline phosphatase, up to 
15 days after a general anaesthetic with propofol and 
nitrous oxide (Robinson et al. 1985). The pharmacokinetics 
of P~opofol given by infusion were not affected ~arkedly by 
moderate cirrhosis (Servin et al. 1990) . . 
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3.6.2: Effects on renal function 
Propofol has not been reported to have adverse effects . 
on renal function. In uraemic patients undergoing renal 
·transplantation (Kirvela et al. 1991), the pharmacokinetics 
of propofol, following a single bolus injection of propofol 
(2~O mg/kg), were similar to those in patients with normal 
kidney function. 
3.6.3: Effects on coagulation 
The emulsion in which propofol was .. reformulated 
resembles Intralipid, which has been associated with 
alterations of blood coagul~tion (Burnham et al. 1982). 
With one possible exception (Newman et al. 1987), studies 
have failed to show that propofol changes the coagulation 
profile as measured by thrombin time, prothrombin time, 
partial thromboplastin time, fibrinogen titre~ fibrin 
degradation products, and platelet count (Kay et al. 1985). 
In addition, propofol was found to have no apparent effects 
on platelet function (Mayne et al. 1~88). 
3.6.4: Effects on adrenal steroidgenesis 
In man, when used as a single induction dose ·of 2.5 
" 
mg/kg, propofol did not block cortisol and aldosterone 
secretion in response to surgical stress or ACTH (Fragen et 
al. :19~7). In contrast, using the same dose of propofol for 
inductiori, followed by a continuous infusion (4.4 mg/kg/h), 
Kay and colleagues (1985) found a transient decrease in 
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plasma cortisol concentration 30 min after induction of 
anaesthesia (Kay et al. 1985), but cortisol concentration 
was riot significantly different from baseline. Propofol was 
found to have no effect on plasma cortisol concentrations, 
and the response to the Synacthen test was normal, with a 
significant increase in cortisol concentration 30 and 120 
min after Synacthen administration. 
3.7: Side effects 
- 3.7.1: Pain on injection 
The most frequent side effect associated with the use 
of propofol has " been pain on inj ection. Collation of data 
from a total of 1,465 patients found that injection of 
propofol into a vein in the dorsum of the hand (n = 428) 
was painful . in 28.5% of cases. However, if the injection 
was into the large veins of the forearm or antecubital 
fossa (n= 821) this figure fell to 6% (Stark et al. 1985). 
A similar incidence was reported in a comparative study of 
propofol as an induction agent in unpremedicated patients. 
The incidence of pain on injection in the antecubital fossa 
and dorsum of the hand, respectively, were 8 and 31% for 
propofol (n = 100),4 and 5% for thiopentone (n = 100), 14 
and 29% for etomidate (n = 50) and 18 and 41% for 
methohexitone (n = 50) (McCollum & Dundee 1986). 
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3.7.2: Excitatory & respiratory 
Excitatory and respiratory effects that occur during 
induction are generally considered as side effects of the 
anaesthetic, although their incidence will to some extent 
be dependent upon other drugs that are used and the skill 
of ~he anaesthetist. In the studies reviewed by Stark et 
al. (1985) excitatoryeffects (movement, twitching, hiccup, 
" 
tremor etc.) were seen in 14% of 1459 inductions with 
propofol~ Apnoeic episodes are more frequently seen; 
McCollum and Dundee (1986) reported that apnoea of more 
than 30 seconds duration occurred in 44% and 24% of 
unpremedicated patients who received propofol 2.5 and 2 
mg/kg, respectively (n = 50 for each dose) In comparison, 
the figures for methohexitone 1.5 mg/kg, etomidate 0.3 
mg/kg and thiopentone 5 mg/kg were 20, 0 and 38%, 
respectively. In some instances the duration of apnoea with 
propofol ca~. exceed 60 seconds (Goodman et al. 1987); this 
will depend to some extent on the induction procedure 
(bolus dose or titrated increments), and it is likely to be 
exacerbated by the concomitant use of opioids. 
3.7.3: Nausea and vomiting 
A particular feature of propofol anaesthesia is the 
low occurrence of postoperative nausea and vomiting, with 
an overall incidence of about 2 to 3%. In the comparative 
studies 'included in this analysis 13 % of patients who 
received thiopentone (n = 79) and 10% of p.atients who 
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received methohexitone (n = 86) either vomited or became 
nauseous (Stark et al. 1985). 
3.7.4: Bradycardia 
Isolated cases of bradycardia have been seen during 
propofol anaesthesia. These were often associated with 
surgical procedures that produce vagal stimulation 
(Henriksson et al. 1987) and were easily controlled by 
administration of ' atropine, although persistent bradycardia 
-
which was resistant to both atropine and - isoprenaline 
(isoproterenol), and where heart rate recovered slowly only 
after propofol infusion was stopped has been reported in 1 
patient (Thomson & Yate 1987). 
3.7.5: Anaphylaxis 
Fourteen patients who had a life-threatening reaction 
within a few minutes after receiving propofol (Diprivan) 
were investigated for anaphylaxis 4-6 weeks after the 
incident by Laxenaire et al. (1992). Three kinds of 
immunologic tests were carried out: skin tests (prick tests 
and intradermal tests with the drugs used and Intralipid, 
the solvent for propofol), a leukocyte histamine release 
test, and a radioimmunoassay (RIA) of immunoglobulin E 
(IgE) against propofol and muscle relaxants, when they had 
been given with propofol. It had been previously shown that 
these were always negative in patients anaesthetized with 
propofol without any complications. Thirteen of the 14 
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patients had at least one positive test supporting 
hypersensi t i vi ty to propofol i 2 pat ients had three tests 
positive; 4 had two tests positivei and 7 had one test 
positive. The skin tests with Intralipid were negative in 
4 patients whose tests with propofol were positive. Two 
patients who had been given muscle relaxants at the same 
time as the propofol had positive IgE-RIA to both drugs. In 
one patient, results of all the tests remained negative, 
and the mechanism involved in the reaction remained 
unidentified. It is note-worthy that 9 patients of 14 had 
allergic histories that were known before the anaesthetic 
(atopYi allergy to antibiotics, muscle relaxants, 
lidocaine, colloids) and that none of the patients had ever 
recei ved propofol or I nt ra li p id before. It i s possible 
that the IgE that linked abnormally with the pr opofol had 
specific binding sites for the phenyl nucleus and the 
isopropyl groups, which are present in propofol and many 
other drugs. 
4: Clinical use 
Propofol has proven to be a reliable anaesthetic that 
can be ·used for both induction and maintenance of 
anaesthesia in most common surgical procedures, either in 
'standard' anaesthetic practice or as part of total 
intravenous anaesthesia. Comparative studies have show that 
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it is at least as effective as other intravenous 
anaesthetics in most respects, with both potential 
advantages and disadvantages in individual situations. In 
outpatient surgery, rapid return to normal psychomotor 
function is clearly important. Propofol also offers a 
particularly low incidence of postoperative nausea and 
vomiting, which is desirable in any setting, but again may 
be especially beneficial in outpatient surgery. The 
incidence of excitatory effects during surgery under 
propofol anaesthesia is also low and propofol is superior 
to methohexitone in this regard. Propofol infusions, as not 
depress adrenal responsiveness to , ACTH during short term 
administration, as occurs with etomidate. 
, . 
Disadvantages of propofol include pain on injection, 
a relatively high incidence of apnoea, and blood pressure 
reductions that may occasionally be marked. However, in 
studies to date the magnitude of these effects was such 
that their management during anaesthesia was 
straightforward in most patients. 
Propofol has been used for three main clinical 
app~ications; 
a) Intravenous bolus for induction of anaesthesia. 
b) Intravenous infusion or repeated bolus for 
maintenance of anaesthesia. 
c) Intravenous infusion or repeated bolus for sedation. 
51 
4.1: Anaesthesia induction 
The ideal intravenous induction agent possesses 
characteristics which include rapidity of onset and 
recovery, reliability of action (smooth onset without 
excitatory effects or respiratory distress), water 
solubility, lack of allergic responses and tissue toxicity, 
and lack of hemodynamic effects. Propofol possesses a high 
degree of lipophilicity and a short half-life which make it 
suitable for intravenous induction with rapid access to the 
brain and subsequent rapid recovery due to redistribution 
and elimination. Induction doses ranged from 2 to 3 mg/kg. 
In those over 60 years old, 1.5 mg/kg is adequate (Dundee 
et al. 1986) . . The induction dose is also reduced by 
premedication with benzodiazepines or opiates (Thomas et 
al. 1988). 
Propofol has been compared with other intravenous and 
inhalation anaesthetics for induction of anaesthesia in a 
range of general surgical procedures. Comparisons with 
methohexitone for both induction and maintenance (in 
combination with nitrous oxide) always found propofol to be 
at "least as effective as methohexitone, irrespective of 
premedication and the use of additional analgesics. 
Recovery from propofol anaesthesia was often significantly 
faster. Propofol seems to produce a higher incidence of 
apnoea on induction than methohexitone, but there is less 
movement during the induction period with propofol. The 
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latter was particularly apparent when no premedication or 
other drugs were given (analgesia being provided by 
regional blockade), when the incidence of movement was 75% 
with methohexitone but only 20% with propofol (Mackenzie & 
Grant 1985). 
Propofol has also been compared with thiopentone for 
induction and again propofol was associated with 
significantly shorter recovery times and was found to be 
superior by anaesthetists' overall assessments (Henriksson 
et al. 1987) in short procedures. 
4.2: Anaesthesia maintenance 
Propofol is the only currently available intravenous 
anaesthetic that is suited for maintenance of anaesthesia. 
This is due to its favourable pharmacokinetic profile which 
avoids the accumulation seen with prolonged thiopental 
administration, the preservation of adrenal steroidogenesis 
(Kay et al. 1985) (in contrast with etomidate infusions), 
the ability to provide easily controllable depth of 
anaesthesia, and relative freedom from excitatorY ,effects, 
which occur with alternative agents such as methohexital 
(Kay 1986). 
Whether maintenance of anaesthesia was by intermittent 
bolus injections or continuous infusions of propofol, 
analgesia provided with nitrous oxide, alone or in 
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combination with opioids, recovery has been rapid in all 
studies (mean recovery time of -15 minutes or less) (Mark et 
al. 1988), despite a varying duration of anaesthesia from 
6 minutes up to 3 hours. 
Use of propofol for both induction and maintenance of 
anaesthesia was also reported to be a suitable alternative 
" 
to induction with thiopentone and maintenance with 
inhalation anaesthetics halothane, isoflurane and enflurane 
and recovery was often quicker after propofol anaesthesia. 
Thus, propofol compares well with other intravenous and 
inhalation anaesthetics in a wide range of general surgical 
procedures, and results in more ;rapid recovery in most 
situations. Several authors have commented additionally on 
the good 'quality of recovery' after propofol, with regard 
to clear headedness and alertness (Henriksson et al. 1987; 
Mackenzie & Grant 1985). 
The su~tability of propofol for infusion, together 
with important advances in infusion technology, have 
resulted in an upsurge of interest in total intravenous 
anaesthesia. The technique has a number of important 
pra~tical advantages over inhalation methods, including the 
provision of good surgical access in oral and airway 
procedures, the ability to avoid nitrous oxide, and 
compatibility with jet ventilation and airway laser surgery 
techniques. Total intravenous anaesthesia with propofol 
provide~ a versatile and effective anaesthetic technique 
which avoids the pollution of the working . envi~onment 
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caused by the use of inhalational agents. 
coates and coworkers described dose requirements 
effective dose 50 (EDso) of 3.24 mg/kg/h and effective dose 
95 (ED9S) of 5.46 mg/kg/h. The average rate of infusion 
varied and was reported as high as 11.5 mg/kg/h (Coates et 
al; 1985). 
Infusions of propofol and an opioid (without nitrous 
oxide) have been combined as general anaesthesia. Combined 
infusions were first reported in 1985 by DeGrood et al. 
'l 
uSJ.ng fentanyl and propofol with good·· success at 
controlling anaesthetic depth and hemodynamic changes. 
Because oi their similar pharmacodynamic characteristics 
(rapid onset and short duration of action), it seems that 
propofol and alfentanil would be ideal and complementary 
agents for total intravenous anaesthesia. When these two 
agents were administered together for orthopaedic or ear, 
nose and throat procedures, anaesthesia proceeded smoothly 
with predictable changes in hemodynamics after induction 
and intubation. Emergence from anaesthesia was rapid (time 
from end of infusion until patient being oriented: 12.8-
18:~minutes). In the recovery room patients were described 
as fully alert and clear headed (steegers et al. 1988). 
If propofol is to be used by continuous intravenous 
infusion, then it is likely that sophisticated 
mic'roprocessor-controlled infusion devices will allow 
stable plasma concentrations of the drug to be achieved 
. rapidly. An initial assessment of such an infusion device, 
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which was aimed at a constant blood level of 2.5 ~g/ml, 
demonstrated that stable concentrations of the drug could 
be achieved. Taking the 20 patients .studied as a group, 
induction of anaesthesia was not associated with 
hypotension. The time taken by the microprocessor to 
achieve stable concentrations was not reported (Schuttler 
et al. 1988). A similar study was carried out using a 
different microprocessor system aiming for a target 
concentration of 3 p.g/ml (Roberts et al. 1988). This 
concentration was reached within 10 minutes. The blood 
pressure and heart rate decreased over the first 15 minutes 
of the study. It is also possible to achieve a stable 
plasma concentration rapidly using a manually controlled 
" 
" 
infusion scheme. This involved making four rate adjustments 
in the first 20 minutes, but achieved stable concentrations 
within 2 minutes of start of infusion. Again, these authors 
suggestedth~t this technique provided better hemodynamic 
stability during induction than a loading dose of 2 mg/kg. 
Computer-controlled infusion schemes will result in a 
stable mean concentration of drug in a group of patients. 
Howeyer, the standard deviation may be as large as 30% of 
the target level (Tackley et al. 1987; Roberts et al. 
1988) . 
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4.3: Use in sedation 
Sedation of critically ill patients in the intensive 
care setting traditionally involves the use of 
benzodiazepines and opioids, which may 
recovery, respiratory depression, and 
stasis. There have been a number of 
cause prolonged 
gastrointestinal 
reports of the 
successful use of propofol by continuous infusion for 
sedation in intensive care unit patients with a variety of 
illnesses, including cardiac surgery, head injury, acute 
respiratory failure, septic shock, and acute tubular 
necrosis (Robert & Deegan 1992). The duration of sedation 
was 8-189 hours and the mean dosages used varied from 0.79 
to 2.88 mg/kg/hr, . reflecting the different ages and 
conditions of the patients in the studies. In each study, 
adequate sedation was achieved without difficulty. 
Su~plernental ~ opioid boluses were required in each case but 
significantly less than with midaiolam sedation. Recovery 
was also very satisfactory (Robert & Deegan 1992). 
Administration of propofol by continuous infusion or 
intermittent bolus ' has been found to be suitable for 
sedation during regional anaesthesia or during day case 
endoscopies, comparing ~avourably with midazolarn and 




PROPOFOL CONTENT ANALYSIS 
1: Introduction high-pressure liquid chromatography 
High pressure liquid chromatography (HPLC) has become 
" 
the 'fastest growing analytical technique. The practice of 
liquid chromatography developed from open column, gravity 
fed systems utilizing effluent collection, to using various 
analytical techniques, such as evaporation to dryness and 
subsequent , dilution and/or reactions followed by 
Ultraviolet-visible and infrared spectroscopy, to a totally 
instrumental methodology. Decreases in column packing 
diameters produced proportional increases in solvent flow 
resistance, and as a result, constant flow and constant 
pressure liquid pumping systems were develo~ed and 
introduc~d. Sample introduction by simply adding the sample 
to " the head of the column was no longer practical, and 
liquid ' syringe and valve injectors were added for sample 
introduction. The efficiency of HPLC allowed very small 
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samples to be used, and the classical methods of collecting 
effluents for further analysis were replaced by using low 
dead volume detectors coupled with strip chart recorders. 
The development of small diameter packing materials 
an~ columns allowed the chromatographer to perform 
separations faster and with greater resolution than had 
previously been attainable. HPLC has become the mos t 
popular chromatographic method, becaus e HPLC i s not limited 
to sample volatility and thermal stability as is gas 
chromatography. Nearly all classes of organic compounds can 
be separated by this efficient and faster analytical 
technique. 
The previously reported method for propofol using 
high-pressure liquid chromatography and ultraviolet 
detection of the indophenol derivative (Adam et al. 1981) 
was not considered sufficiently sensitive (the limit of 
" 
quantification was 15 ng/ml) for the monitoring of all 
clinical studies. The combination of high-pressure liquid 
chromatography and fluorescence detection has improved the 
sensitivity of propofol measurements. The method described 
-; in this chapter is more rapid and simpler to use than the 
indophenol procedure and has improved the sensitivity of 
analysis, with the lower .limit of quantification being 2 






delivery 1----1 introduction H Column 







Fig 3-1: HPLC system diagram 
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waste 
2: Methods of propofol content analysis 
Refer Appendix for source & manufacturer of all 
reagents and equipment. 
This method was based on that published by Chan & So 
1990 with slight changes in the mobile phase composition. 
2.1: Reagents and solutions. 
2.1.1: Sodium dihydrogen phosphate O.lM M=137.99 glmol 
Take 1.38 g NaH2 P04 .H20 dissolved in Mill-Q water 
Adjusted to pH 4.66-4.7 by PH-Meter with dilute Sodium 
hydroxide solution or Hydrochloric Acid and then diluted to 
100 ml with Mill-Q water. 
2.1.3: Tetramethylammonium Hydroxide Solution. 
Take 0.375 g Tetramethylammonium Hydroxide solid 
dissolve in 1.5 ml absolute Methanol and then dilute with 
18.5 ml 2-Propanol (IPA). 
2.1.4: Acetonitrile CH3 CN 
2.1.5: Acetic acid CH3COOH 
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2.2: Standard solutions. 
2.2.1: Propofol standards. 
Weigh a drop of 99% pure propofol stock solutions 
dissolved in 100 ml absolute methanol. Using this stock 
solution according C1V1 =C2V2 , prepare 3 standard solution 
containing 100, 10, 1 mcg/ml, stored at 4°C, but prepared 
fresh each two months. 
2.2.2: Internal standard. 
0.0012 g Thymol Crystals dissolved in 100 ml absolute 
methanol. Take a small aliquot and then dilute to 10 times 
with absolute methanol to produce 12 ng/ml. Stored at 4°C, 
also prepared fresh each two months. 
2.2.3: Control standard. 
Take 40 ml of whole blood and divide into 2 tubes. In 
one tube, add 20 JlI of 100 mcg/ml propofol standard 
solution to prepare 100 ng/ml control. In the other tube, 
add 100 p.l of 100 mcg/ml propofol standard solution to 
prepare 500 ng/ml control. Mix for one hour at room 
temperature and transfer 0.7 ml aliquots of the prepared 
control levels into 1.5 ml eppendorf tubes and store at 4°C 
for later use. 
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2.3: Mobile phase 
Take 660 ml Acetonitrile, add 3.4 ml Acetic acid and 
dilute to 1 litre with Mill-Q water. The mobile phase is 
mixed for one hour at room temperature using a magnetic bar 
on stir plate mixer, filtered with filter paper of type GV 
with 0.22 J1.m pore size and degassed in an ultrasonic 
cleaner. 
2.4: High-pressure liquid chromatography 
The high-pressure liquid ch~omatography apparatus 
consisted of a metering pump solvent-delivery system set to 
, . 
deliver a solvent . (66% Acetonitrile as described 2.3: 
Mobile phase) at a flow-rate of 1.7 ml/min and 700 PSI 
operating pressure. A metering pump was used in conjunction 
with an inje~tion system and a column Nova-pak C18 aDS in 
a Waters ReM 8x10 radial compression module. The 
fl~orescence spectrophotometer was used at excitation 
wavelength of 276 nm & emission wavelength of 310 nm, and 
both monochromator slit widths were 10 nm. The fluorescence 
spectrophotometer was attached to an integrator and the 
signals were recorded using a hot-pen chart recorder. 
63 
2.5: Quantification 
Calibration standards were prepared in expired whole 
blood by addition of known amounts of propofol (50, 100, 
250, 500, 1000, 3000 ng/ml) and a constant amount of thymol 
(50 - ~l, 12 'ng/ml) corresponding to the median concentration 
of the calibration series under exami nation . The s t andards 
wer e treated in an identical manner to the unknown samp~es. 
The ratio of the peak heights derived from propofol and 
thymol in the standards were used to construct calibration 
curves from which unknowns were quantified. Each 
concentration was done in triplicate. 
A calibration graph was prepared by the addition of 
known quantities of propofol to aliquot of control blood 
and extracted according to the below 2.6: Procedure. The 
peak-height ratio of propofol to thymol was plotted against 
the concentr.ation of propofol and the concentration of 
propofol in the samples was calculated using the regression 
parameters obtained from the calibration graph. 
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Table 3-1: I I I I I I 
Calibration of Propofol standard 
in Whole blood 
'. 
Propofol Peak height of Peak height of Ratio Mean S.D. C.V. 
1.0 ng/rol Propofol Internal standard (%) 
50A 201652 2077037 0.0971 
508 257874 2534218 0.1018 0.0990 0.0018 1.83 
50C 233445 2375293 0.0983 
.. 
1- 100A 490064 2588574 0.1893 
1008 418834 2060215 0.2033 0.1945 0.0059 3.03 
100C 505763 2651274 , 0.1908 
!- 250A 875590 " 1775794 0.4931 
2508 1168430 2282474 0.5119 0.4997 0.0081 1.63 
250C 1100427 2227067 0.4941 
-
-
500A 1899784 2171686 0.8748 
-
5008 2259874 2406278 0.9392 0.9114 0.0244 2.68 
I- 500e 2059410 2237619 0.9204 
I-
-
1000A 3029338 1516818 1.9972 
-
10008 3888829 2061912 1.8860 1.8744 0.0896 4.78 
r- 1000e .. 3846022 2210350 1.7400 
I-
_ 2000A 3418218 900556 3.7957 
_2000B ,2147245 600193 3.5776 3.7272 0.0997 2.68 
_ 2000C 2906402 763161 3.8084 
" 
:--
' 1_ 3000A .5426330 963884 5.6297 
'. 
t-- 3000B 3680522 601426 6.1197 5.7548 0.2433 4.23 




Constant -0.01079 y = mx + b 
Std Err of Y Est 0.12725 r = 0.9962 
R Squared 0.99625 m = 0.001904 
No. of Observations 21 b = -0.01079 
Degrees of Freedom 19 f = 525 
X Coefficient(s) 0.001904 
Std Err of Coef. 0.000027 









o 500 1000 1500 2000 2500 3000 
Propofol concentration (ng/ml) 
Fig 3-2: Calibration of Propofol standard in Whole blood 
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2.6: Procedure 
Samples were whole blood in heparinized tube stored at 
4°C, until analysis. 0.5 ml heparinized whole blood was 
transferred into a 15 ml silanized and screw-cap glass 
tube. To this was added 50 III internal standard (as 
described 2.2.2: Internal standard) and 1 ml (0.1 M) Sodium 
dihydrogen phosphate (PH 4.6) (as described 2.1.1: Sodium 
dihydrogen phosphate) and 5 ml cyclohexane (as described 
2 • 1. 2 : Cyclohexane). The tube was screw- capped and the 
mixture was tumbled (33 rpm, 15 min) in a rotary tumbler. 
It was then centrifuged for 5 minutes at 3000 rpm, and at 
20°C. After centrifugation, the upper organic extract was 
transferred into a tapered, silanized evaporating tube 
containing 50, ~l of Tetramethylammonium Hydroxide solution 
(as described 2.1.3: Tetramethylammonium Hydroxide 
Solution), and the cyclohexane extract was evaporated to 
dryness under a stream of nitrogen gas at 37°C in a water 
bath. The dried residue was dissolved in 80 III acetonitrile 
(as descr ibed 2. 1. 4 : Acetoni tr i le) and stored in an ice 
bath .. An aliquot (10-50 ~l) of the solute was submitted to 
high-pressure liquid chromatography analysis. Typical 
chromatog~ams of extracts containing propofol are shown in 
Fig 3-3: Chromatogram of extracts containing propofol & 
internai standard. 
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Fig 3-3: Chromatogram of extracts containing propofol 
& internal standard. 
Concentration of propofol 
Ratio . . = ------------------------------------
concentration of Internal standard 
Peak height of propofol 
= ----------------------------





Concentration of propofol = Ratio x f 
= 3.3756 x 525 
= 1772.19 ng/ml 
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2.7: Throughput: 
2.7.1: First working day. 
a) Prepared mobile phase: Diluted, mixed, filtered and 
degassed (as described 2.3: Mobile phase). 
b) Cleaning the high-pressure liquid chromatography system, 
· using methanol with a flow-rate of 0.1 ml/min overnight. 
c) Prepared the propofol standard, the internal standard 
and the control standard (as described 2.2: Standard 
solution). 
2.7.2: Second working day. 
a) Calibration standards added a known amount of propofol 
(50, 100, 250, 500, , 1000, . 3000 ng/ml) and a known amount 
of thymol (50~1 12 ng/ml) to 0.5 ml of expired whole 
blood. Each concentration was done in triplicate. Total 
of 18 standards. (as described 2.6: Procedure) 
b)-All the prepared calibration staridard were then injected 
to HPLC system. The total run time per trial was 8 
minutes. Some calibration standards were reinjected if 
ne,cessary. The time required to finish the HPLC run for 
all the standards is about 4 hours. 
2.7.3: Third working day. 
The peak-height ratio of propofol to thymol was 
calculated and, a calibration graph was obtained from the 
above calculated result (as described 2.5: Quantification). 
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The regression parameters was calculated at the same time. 
2.7.4: Fourth working day. 
a) Concentration of unknown samples were determined by 
preparing a set of calibration standards containing 3 
different concentrations of propofol along with 2 
control standards and 15 unknown samples from patients. 
(as described in 2.6: Procedure). 
b) All th~ prepared calibration standards, control 
standards and unknown samples were injected into the 
HPLC system with a run time of 8 minutes per injection. 
2.7.5: Fifth working day. 
The concentration of propofol in the unknown samples 
was calculated using the regression parameters obtained 
from the calibration graph. A total of 20 samples (15 test 
samples add 3 standards and 2 control standards) were 
tested. 
The remaining unknown samples were . processed in a 
similar manner. 
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3: Results of propofol content analysis 
3.1: Calibration standard of propofol (Linearity) 
The propofol standards, control standards and internal 
standards were prepared fresh every two months. 
In each of my experiments, I included 3 propofol 
standards (50, 250, 1000 ng/ml propofol) and 2 control 
standard (100, 500 ng/ml propofol) with the kest samples 
and the results were consistent. A linear relationship was 
, obtained between the ratio of the peak height of propofol 
to that of thymol and the amount of propofol added to blood 
over t he range 2- 3000 ng / ml . Specimens with propofol 
concentrations above 3000 ng /ml was diluted to decrease t he 
propofol concentration to within the calibrated range of 
the assay. No change in the slope was observed with 
different batches of blood used . These results indicate 
that the method permits the determination of propofol in 
blood over wide ranges of concentration. The calibration 
grapns were linear over the r ange 2- 3000 ng/ml with 
coefficients of variation ranging from 0.3774 to 7 ~ 8617%. 
The between-batch coefficient of variance was 9.7850% at 50 
ng/ml, 8.5220% at 100 ng/ml, 8.1776% at 250 ng/ml, 5.1353% 
at~SOQ hg/ml, 4.2039% at 1000 ng/ml, and 7 . 6469% at 3000 
ng/ml, while the limit of detection was approximately 2 


























































































































































































































































































































































































































































































































































































































































3.2: Control standard of propofol 
3.2.1: Reproducibility 
Pooled control whole blood is spiked with known 
concentration of propofol (100 ng/ml and 500 ng/ml) stored 
at 4°C. These pooled controls were assayed for propofol 
content on Day 0,1,3,5,7, . 14, . 21,30, . 60,90. (1 trial 
each day). 
3.2.1.1: Intraassay coefficient of variation (one 
analysis day) 
The intraassay coefficient of . variation Cn = 5) of 
propofol in whole blood, which is done on one analysis day, 
" 
was 6.24% at 100 ~ng/ml and 6.10% at 500 ng/ml (described in 
Table 3-3: Intraassay coefficient of variance and recovery 
for propofol in whole blood) . 
3.2.1.2: Interassay coefficient of variation (10 
analysis days) 
The interassay coefficient of variation (n = 10) for 
propofol in whole blood, which is done on ten analysis 
days, was 3.18% at 100 ng/ml and 1.81% at 500 ng/ml 
(described in Table 3-4: Interassay coefficient of variance 













































































































































































































































































































































Interassay· coefficient of variance 
for Propofol in Whole blood 
" 
Day Control Low Control High 
Concentration (ng/ml) Concentration (ng/ml) 
0 100 483 
1 102 505 
3 101 487 
5 100 489 
7 100 488 
" 
14 .. 96 490 
30 90 457 
Mean (n = 7) 98 485 
S.D. 3.12 8.81 
C.V. (0/0) 3.18 \ . 1.81 
3.2.2: Recovery 
The extraction efficiency can be estimated by 
comparing the results of experimental and the theoretical 
amount of Propofol in whole blood. The theoretical value is 
based on the knowledge of the amount of Propofol spiked 
into the specimens. The experimental value is based on the 
amount obtained by comparing the peak height ratio of the 
spiked specimens against those from the calibration curve. 
The extraction recovery results obtained (n = 5) for 
propofol relative to the internal standard (Thymol) in 
' whole blood was 104% at 100 ng/ml and 99% at 500 ng/ml 
(described in Table 3-3: Intraassay coefficient of variance 
and recovery for propofol in whole blood). 
3.2.3: stability 
Pooled whole blood is divided into two tubes. Known 
volumes of standard Propofol is spiked into these tubes to 
prepare pooled controls containing 100 ng/ml and 500 ng/ml 
of Propofol respectively. Aliquots of 0.7 ml were ' 
transferred into 1.5 ml eppendorf tubes and stored at 4°C 
for subsequent use on separate analysis days to check for 
stability during storage. The stability results obtained (n 
= 10) for propofol control in whole blood analysis. 





Stability of Propofol Control standard 
in Whole blood 
Day Control Low Control High 
Concentration (ng/ml) Concentration (ng/ml) 
" 
.' 
0 100 483 
1 102 505 
3 101 487 
" 
5 100 489 
7 100 488 
14 96 490 
21 88 471 
30 90 457 
" 
60 85 473 
90 86 453 
Mean(n = 10) 95 480 
S.D. 5.89 12.74 




















































































































































































4:~Discussions of prop~fol content analysis 
4.1: -Calibration standard of propofol. 
The previously reported method for propofol using high 
pre~sure liquid chromatography (HPLC) and ultraviolet 
detection of the indophenol derivative (Adam et al. 1981) 
was not considered sufficiently sensitive (limit of 
quantification ca. 15 ng/ml) for the monitoring of all 
clinical studies, The combination of HPLC and fluorescence 
detection has improved the sensitivity of propofol 
me~surements. The method described- is more rapid and 
simpler to use than the indophenol procedure and has ,an 
improved limit of quantification of ca. 2 ng/ml (Plummer 
1987). Our experimental and analytical method is similar to 
Plummer IS (as described in tlvYs chapter 2: Methods for 0 
/' " \ Z t "1 r.. '-1 1"'\1 :: 'i (f v"f., 
propofol content analysis) except the following points. ~J ~ -
a) In our procedu~e, blood samples were collected in 
heparinizied tubes and 0.5 ml of blood were taken each 
time, 50 ~l _ of internal standard solution was added to 
each sample. Plummer's blood samples were collected 
in oxalated tubes and 1 ml was taken each time. with 
20 ~i internal standard solution diluted to an 
approximate working concentration was added to each 
sample). 
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b) The HPLC mobile phase consisted of 660 ml acetonitrile 
340 ml Mill-Q water (containing 3.4 mL Glacial acetic 
acid). Plummer's mobile phase consisted of 600 ml of 
acetonitrile , 400 ml of distilled water and 1 ml of 
trifluoroacetic acid. 
c) Our solvent flow rate was 1.7 ml/min and 700 psi 
operating pressure, while Plummer's flow rate was 1.5 
ml/min. 
The method was linear from 2 ng/ml to 30QO ng/ml . The 
concentration of propofol in standard (50, 100, 250, 500, 
1000, 3000 ng/ml) and control (100, 500 ng/ml) samples were 
calculated using the regression parameters obtained from 
the calibration graph. 
In some instances, we used plasma as sample matrix for 
preparing th~. calibration standards instead of whole blood 
due to the unavailability of the whole blood. We compared 
the results of calibration standards prepared using either 
whole blood or plasma as sample matrix and found that there 
Was no signifi cant d i ffer ence in the value of the s l ope 
between the two matr i xes . (as described Tabl e 3-7 : 
Calibration of pr opofol standard i n whole blood & in 
plasma, and Fig. 3-6: Comparison of results obtained f r om 














































































































































































































































































































































































































































































































































































































































































































































































































































































































Calibration of Propofol Standard 
in Whole blood & Plasma 
i-
-
I- Whole blood Plasma 
.... ng/ml Ratio Mean S.D. C.V. (%) ng/ml Ratio Mean S.D. C.V. (%) 
I-- 50A 0.11 50A 0.10 
r- 50B 0.11 0.11 0.0041 3.66 50B 0.12 0.11 0.0089 8.33 
__ 50C 0.12 50C 0.10 
r-1OOA 0.23 100A 0.20 
1 __ 1008 0.21 0.22 0.0089 4.10 100B 0.23 0.21 0.0111 5.21 
1_100C 0.21 100C 0.21 
.. 
t--25OA 0.41 250A 0.46 
1--25OB 0.44 0.45 0.0289 6.47 250B 0.51 0.50 0.0267 5.33 
1--35OC 0.49 250C 0.53 
~OOA 0.95 500A 0.94 
1--5OOB 0.97 0.96 0.0089 0.93 500B 0.99 0.98 0.0267 2.72 
1_5OOC 0.95 500C 1.01 
r-2900A 2.24 1000A 1.92 
t-2.000B 2.03 2.08 0.1044 5.01 1000B 2.13 2.03 ' 0.0711 3.51 
~OOOC 1.98 1000C 2.03 
r-2900A 6.24 3000A 5.93 
I-!OOOB 5.85 6.26 0.2911 4.65 3000B 6.03 5.93 0.0711 1.20 
r-29ooc 6.70 3000C 5.82 
t--- Regression Output: Regression Output: 
t---
--
Constant -0.0333 Constant 0.01335 
--
Std Err of Y Est 0.16406 Std Err of Y Est 0.05938 
--
R Squared 0.99486 R Squared 0.99924 
t--- No. of Observations 18 No. of Observations 18 
I--- Degrees of Freedom 16 Degrees of Freedom 16 
1---- I I 
t--- X Coefficient(s) 0.0021 X Coefficient(s) 0.00197 
'--




















































































































































































Table 3-8: compariso~ of results obtained from the 
calibration of propofol by our methods and plummer's (1987) 
-----~--------------------------------------------------Calibration 











Table 3~9: Comparison of results obtained from _~he between-
batch coefficient of variation by our method and plummer's 
, (1987) 
-- ------------~----------------------------------------Our results Plummer's results 
" 
Mean S.D. C.V. Mean S.D. C. V. (ng/ml) (ng/ml) (%) (ng/ml) (ng/ml) (%) 
-------------~-----------------------------------------
50 0. ,0104 9.7850 50 0.004 8'.0 
100 0.0178 8.5220 34 0.003 8.8 
250 0.0398 8.1776 57 0.007 12.3 
500 0.0488 5.1353 1710 0.05 2.9 
1000 0.0808 4. '2039 4110 0.14 3.4 
3000 0.4602 7.6469 5920 0.26 4.4 
-------------------------------------------------------
Although the limit of detection in the method used by 
Plummer is similar to our method which is 2 ng/ml, we have 
the advantage of detecting it using only 0.5 ml of sample 
as against 1 ml which was used in his method. The 
coefficient of variations are similar. 
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4.2: Precision and accuracy of analytical method. 
Precision and accuracy determine the error of analysis 
and are the most important criteria for judging the 
performance of an analytical method~ Normally, precision 
refers to the variation of scatter of the measurements 
about the mean value. Some analysts use the terms 
reproducibility and repeatability instead to refer to the 
scattering of the assay results obtained by the same method 
but: under different and same conditions (i. ~. operator, 
laboratory, instrument, time), respectively. For analysis 
of drug and other sUbstances in biological samples f or 
pharmacokinetic evaluation, precision and accuracy are most 
often estimated l5y analysis of replicate seeded control 
samples at s evera l concentration leve ls, preferably three 
or more, over the expected concentration range' of the 
samples. The precision of the analysis is estimated as the 
relative standard deviation (coefficient of variation) of 
the measured concentrations of replicate samples and the 
accuracy is estimated as the percent differences (bias) 
between the mean values and true or known concentrations. 
Wh~n the analysis of the seeded control samples are carried 
out in the same assay run or on the same day the precision 
data are reported as within-day precision as compared with 
between-day precision for which the analysis is performed 
on different days. The criteria for acceptable precision 
and accuracy of the assay results cannot be generalized 
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because both precision and accuracy depend on the 
concentrations of the analyses being evaluated (Thompson 
1988) and the acceptable criteria depend on the purpose of 
the analysis. In the analysis of biological samples for 
pharmacokinetic studies, assay results with <10% relative 
standard deviation and <10% bias may be considered 
acceptable (Geoffrey & Win. 1990). 
In our method, the intraassay (n = 5) of propofol in 
whole blood, which is done on one analysis day, was 6.24% 
at 100 ng/ml and 6.10% at 500 ng/ml (described in Table 3-
3 : Intraassay coefficient of variance and o · recovery for 
propofol in whole blood). The interassay (n = 10) for 
propofol in whole blood, which was done on ten analysis 
days, was 3.18% at ' 100 ng/ml and 1.81% at 500 ng/ml 
(described in Table. 3-4: Interassay coefficient of variance 
for propofol in whole blood). The assay results may thus be 
considered acceptable. 
4.3: Extraction efficiency of analytical method . 
. An initial isolation of drug and metabolites in 
biological samples by means of extraction, protein 
precipitation or other procedures is usually performed 
before these samples are chromatographed to separate the 
drug, metabolites and the internal standard. Sometimes, a 
combination of multiple isolation procedures is necessary 
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in order to allow adequa~e chromatographic separation. Many 
of these sample preparation proqedures cause a loss of the 
drugs or metabolites due to incomplete extraction, 
adsorption, volume loss or co-precipitation. It is seldom 
that the drugs can be completely recovered from the 
bio~ogical samples, but the reduced recovery should be 
minimized by optimizing the conditions for the isolation 
procedures. 
Recovery should also be reproducible. An assay method 
with low but reproducible recovery may be acc~ptable whe~ 
the samples are analyzed with appropriate calibration 
standards. In some literature reports, - the concentration of 
drug found in seeded control samples expressed as the 
percentage of the known drug concentration is called 
"recovery". 
Like precision and accuracy, recovery ' may be 
concentration-dependent and needs to be evaluated over the 
range of the expected concentration in the samples. 
However, good precision and accuracy cannot be obtained 
when the recovery of the analyses is not reproducible. 
In some literature reports, the concentration of drug 
found in seeded control samples expressed as the percentage 
of the known drug concentration is called "recovery". By 
this definition, recovery is the same as accuracy and this 
is the reason that accuracy is reported as "recovery" by 
some analysts. ,AS defined, the recovery should be close to 
100%. However, recovery experiments are usually done when 
BB 
the assay method is b,eing developed or validated. The 
purpose is to obtain an overall high recovery of drugs, 
preferably >75%, from the samples taken through the 
complete analytical procedures. Accuracy, on the other 
hand, is continuously monitored as the samples are 
anal:yzed. 
In our method, the extraction recovery results 
obtained (n = 5) for propofol in whole blood is 104% at 100 
ng/ml and 99% at 500 ng/ml (described in Table 3-3: 
Intraassay coefficient of variance and r~covery for 
propofol in whole blood). 
Our results are thus acceptable. -
4.4: Stability of analytical method. 
Many drugs and their metabolites are relatively 
unstable and may degrade in the biological samples during 
the collection and processing of the fresh samples and the" 
subsequent storage, preparation and analysis of the 
samples. Factors affecting the stability of drugs in 
" 
biological samples are many and should be evaluated based 
on each individual drug. In most pharmacokinetic studies 
the biological samples collected are seldom analyzed 
immediately after collection, but are stored " for later 
analysis. " In our laboratory, the samples were assayed 
within one month. Long-term storage enhances the 
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probability of degradation of the drugs and metabolites in 
the biological samples. ·The analysis of biological samples 
sh6uld be completed before the degradation of the drugs 
occurs. Care must be taken to assure that the measured drug 
concentrations are meaningful and not interfered with by 
sample degradation and other artifacts due to the 
procedures for the collection, processing, storage and 
analysis of the samples. 
Stability of whole blood samples are checked by 
assaying aliquots of a pooled control on separate analysis 
days (n = 10 up to 3 months for whole blood). A slight 
decrease in the amount of propofol was detected after 30 
days. Hence, we assay all the samples within one month. 
(Fig 3-5: Stability of propofol control in whole blood) 




PROTEIN BINDING OF PROPOFOL 
1: Introduction protein binding of propofol 
Drug disposition. i.e. absorption, distribution, 
metabolism and elimination are the major determinants of 
the pharmacokinetic profile of any compound. The 
pharmacological response obtained is, for the majority of 
drugs, related to the concentration of drug at its receptor 
" 
site(s). Thadisposition and ultimate biological effect of 
the drug may be said to be 'controlled' by the extent of 
plasma protein binding, since this is the factor limiting 
the amount of drug available to leave the vaSCUlature and 
gain. access to receptors, tissues and the various sites of 
elimination and metabolism. As a result, any significant 
alteration in plasma protein binding can lead to an altered 
drug distribution and unexpected pharmacological responses. 
A further consequence of a change in protein binding also 
91 
has implication on therapeutic drug monitoring, i.e. 
alteration of a dose according to an individual's plasma 
concentration. 
'At present, two separation methods are widely used: 
ultrafiltration and equilibrium dialysis. 
1.1: ultrafiltration 
In the ultrafiltration of a protein solution 
containing a ligand, the pressure difference forces the 
buffer containing free ligand through a -permselective 
membrane. The total volume of ultrafiltrate plus retentate 
solutions equals the initial solution volume. This method 
of separation of the bound ligand from the free one is 
" 
extremely popular ~ecause of the easy handling of a large 
number of samples, as well as the commercial availability 
of a variety of filtration devices. 
1.2: Equilibrium dialysis 
In a typical equilibrium dialysis experiment the 
macromolecular solution is separated by a semi-permeable 
membrane from the ligand solution. If there is no 
alteration of ligand or protein(s), the system reaches an 
equilibrium state known as "steady state". Since, at steady 
state, ' the free ligand concentrations are equal on both 
sides of -the dialysis membrane, the concentration detected 
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in the compartment containing the protein(s) is due to the 
sum of bound and free drug concentrations, whereas the 
concentration detected in the other side is that of the 
free ligand only. Therefore, the concentration of bound 
ligand is equal to the difference between the total ligand 
concentrations (bound + free) of the solutions present in 
each compartment. 
Equilibrium dialysis is an ideal approach to studying 
the binding of small molecules or ions to macromolecules. 
For example, binding studies are very -important in 
pharmacology. The therapeutic and toxic effects of a drug 
are directly related to the level of unbound drug in the 
blood stream. Drug bound to plasma proteins is 
pharmacologically not effective, therefore it is necessary 
to .determine the level of bound and unbound drug in the 
blood to find out the proper dosage. The extent of drug 
binding varies from one patient to another. Low adsorption 
is an absolute necessity in binding studies because the 
unbound species must be freely permeable through the 
membrane to attain equilibrium. High adsorption leads to 
false results. 
The choice of a particular method depends on the 
stability of the ligand-protein complex and on the accuracy 
needed, i . e. the bound I igand percentage, the binding 
parameters or the molecular recognition ability of the 
protein. Equilibrium dialysis is theoretically the most 
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accurate way to determine free and bound ligands because 
the equilibrium is not ,shifted when aliquots are taken from 
both sides of the dialysis membrane. 
Therefore, equilibrium dialysis was adopted as our 
test procedure. 
2: Methods of protein binding of propofol 
Refer Appendix for source & manufacturer of all 
reagents and equipment. 
2.1: Material & Solution 
2.1.1: Dialysis buffer 
Sorensen's phosphate buffer was prepared by mixing 200 
ml~of Potassium dihydrogen phosphate, M = 136.09 ~/mol with 
800 ml of Di-sodium hydrogen phosphate, M = 137.99 g/mol 
and adjusting the pH to 7.4 using Sodium hydroxide solution 
(iN) or Hydrochloric acid (1N). 
2 •. 1.2: Molecularporous Dialysis Membrane 
The Spectra/por regenerated cellulose membrane has 
proved to be a useful membrane available for laboratory 
dialysis. It carries no fixed charge and does not absorb 
most solutes. Hydrophobic microfiltration membranes are 
often characterized by means of "bubble point" measurements 
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that give an estimate of pore size. These measurements are 
not practical for mo'st dialysis membranes because their 
"pores" are much smaller and because in regenerated 
cellulose membranes the structure is actually a gel. 
Instead, the widely used method to characterize dialysis 
membranes is the molecular weight cut off (MWCO). In this 
method the permeability of the membrane to a series of 
molecules of different molecular weights in solution is 
measured in dialysis experiments. That solute molecular 
weight that is prevented from permeating (retained) to an 
extent of 90% is the MWCO. Spectrum uses this method to 
characterize its dialysis membranes. 
Another method that is also used at Spectrum is the 
measurement of the rate of dialysis. This is carried out by 
placing a solution with a known concentration of a selected 
permeable molecular species on one side (retentate side) of 
the membrane and pure solvent on the other (diffused side) . 
Both are well mixed and the solvent is changed frequently 
so that the concentration of solute is always negligible. 
Under these circumstances, the rate of passage of the 
solute follows first order kinetics, i.e., a plot of the 
logarithm of concentration in the retentate versus time 
follows a straight line. 
To prevent possible absorption of propofol from the 
blood sample into the membrane, immerse the Molecularporous 
dialysis membrane into the Mill-Q water for 24 hours in 40C 
and then discard the water. Add 250 ml Mill-Q water and 100 
95 
~l of propofol (100 mcg/ml) and mix for one hour at room 
te~perature using a magnetic bar on the stir plate. After 
one hour, discard the drug solution and wash the membrane 
ten "times using 250 ml portions of Milli-Q water, 
discarding the washing each time. Finally immerse the 
membrane into 250 ml Sorensen's phosphate buffer (as 
described this chapter 2.1.1: Dialysis buffer) store at 4~C 
prior to use. 
2.2: Equilibrium dialysis 
Equilibrium dialysis was performed using a spectrum 
equilibrium Dialyser. Drug-containing plasma samples or 
protein solutions (1 ml) were dialysed against drug-free 
Sorensen's phosphate buffer (1 ml; pH 7.4) in teflon 
dialysis chambers separated by Spectrapor dialysis membrane 
(As described this Chapter 2.1.2: Molecularporous Dialysis 
Membrane). The effect of drug concentration on protein 
binding was determined within the range of 0.25-3.00 ~g/ml 
of Propofol (the usual therapeutic plasma concentration 
range of the drug). Propofol concentrations in samples were 
assayed by a high~pressure liquid chromatography method as 
described above Chapter Three 2.6: Procedure. Protein 
binding was calculated using the formula: 
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Cp = concentration in plasma after dialysis 
Cbu = concentration in buffer after dialysis 
2.3: Determine the optimum dialysis time to reach 
equilibrium 
The time required for dialysis for each individual 
ligand must be determined experimentally. -Starting with 
specific ligand concentration, a defined operating 
temperature and a buffer system, dialysis is measured as a 
function of time. 
2.3.1: Material 
A. Propofol (3000 ng/ml) was spiked onto blank plasma to 
give a concentration of 3000 ng/ml. The mixture was 
mixed for one hour at room temperature and then store at 
4°C prior analysis. 
B. Sorensen's phosphate buffer (as described this chapter 
2.1.1: Dialysis buffer) . 
C. Spectra/por 2 membranes (Part No's 132678 and 132680) 
D. 1 ml syringes equipped with 3 inch blunt nose 22G 
needles. 
E. Teflon cells. 
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2.3.2: Procedures 
A. Fill the compartments on the left side with plasma 
(containing 3000 ng/ml propofol) and the compartments 
on the right side with the Sorensen's phosphate buffer. 
B. Rotate the Teflon cells at 15 rpm at 37°C. 
C. Empty the cells in accordance with the following 
-schedules. 
Cell No. 1: after 15 minutes 
Cell No. 2 : after 30 minutes 
Cell No. 3 : after 60 minutes 
Cell No. 4 : after 90 minutes 
Cell No. 5: after 120 minutes 
Cell No. 6: after 150 minutes 
Cell No. 7: after 180 minutes 
Cell No. 8 : after 210 minutes 
D. After re~ching equilibrium dialysis, collect the 
plasma and buffer separately using a 1 ml syringe with 
~3 inch blunt nose 22G needles transfer to 1.5 ml 
eppendorf tubes. 
E. A~cording Chapter Three 2.6: Procedure to analysis 
propofol concentration. 
F. Finally, binding parameter are calculated. 
G. Each experiment was done in duplicate. 
98 
, 
~3: Results of protein binding of propofol 
3.1: Results for optimum dialysis time to reach 
equilibrium 







































































































































































































































































































































































































































































































































3.2: Results for reproducibility 
Pooled control , plasma is spiked with known 
concentration of propofol (3000 ng/ml) stored at 4°C. These 
pooled controls were assayed for propofol content on Day 0, 
1, 3, 5, 7, 14, 30. (6 trials each day). Some of these 
pooled controls were,dialysed and the propofol content in 
both plasma/buffer compartments determined. (5 trials each 
day) . 
3.2~1: Intraassay coefficient of variation (One 
analysis day) of propofol in plasma and in protein binding 
The intraassay coefficient of variation (n = 6) of 
total propofol in plasma, which is · done on one analysis 
day, was 1.97% at 3000 ng/ml, and protein bound propofol 
was 0.11% and fr~e propofol 3.65% (described in Table 4-2: 
Intraassay coefficient of variance for propofol in plasma 
& Table 4-3: Intraassay coefficient of variance for 
propofol in protein binding) 
3.2.2: Interassay coefficient of variation (Seven 
analysis days) of propofol in plasma and in protein binding 
The interassay coefficient of variation (n = 42) of 
total propofol in plasma is 2.19% at 3000 ng/ml (described 
in Table 4-4: Interassay coefficient of variance for 
propofol in plasma), protein bound propofol was 0.23% and 
free propofo! was 8.57% (described in Table 4-~: Interassay 




Intraasay coefficient of variance 
for Propofol in Plasma 
Day Sample Concentration 
(ng/ml) 






.. Sample-5 2811 
Sample-6 2904 







Intraasay coefficient of variance 
for Propofol in Protein binding 
Day Sample Buffer Plasma Bound 
'. 
. ' 
Cone. ng/ml Cone. ng/ml (%) 
-
1 Sample-1 71.39 2545 97.19 
~ 
Sample-2 75 .05 2681 97.20 
Sample-3 73 .15 2545 97.13 
.. 
Sample-4 71.35 2692 97.35 
Sample-5 77.41 2529 96.94 
" 
Mean (n = 5) 97.16 
S.D. 0.10 






























































































































































































































































































































Table 4-5: I I I I 
Interassay coefficient of variance 
for Propofol in Protein binding 
Day Sample Buffer Plasma Bound Free 
Cone. ng/ml Cone. ng/ml (%) (%) 
0 Sample-1 80.54 2559 96.85 3.15 
Sample-2 82.7 2750 96.99 3.01 
Sample-3 73.48 2573 97.14 2.86 
Sample-4 72.28 2642 97.26 2.74 
_ Sample-5 70.16 2782 97.48 2.52 
1 Sample-1 71 .39 2545 97.19 2.81 
-Sample-2 75.05 2681 97.20 2.80 
Sample-3 73.15 2545 97.13 2.87 
Sample-4 71.35 2692 97.35 2.65 
Sample-5 77.41 2529 96.94 3.06 
3 Sample-1 69.37 2619 97.35 2.65 
Sample-2 65.58 2599 97.48 2.52 
Sample-3 65.12 2574 97.47 2.53 
Sample-4 67.77 2658 97.45 2.55 
.-
Sample-5 67.13 2796 97 .60 2.40 
5 Sample-1 62.21 2311 97.31 2.69 
Sample-2 60.14 2621 97~70 2.30 
Sample-3 65.09 2486 97.38 2.62 
Sample-4 59 .14 2457 97.59 2.41 
Sample-5 66.53 2574 97.42 2.58 
'·7 Sample-1 57.7 2255 97.44 2.56 
Sample-2 63.67 2418 97.37 2.63 . 
Sample-3 51.35 2091 97 .54 2.46 
Sample-4 62.49 2279 97.26 2.74 
Sample-5 55 ;41 2468 97.75 2.25 
14 Sample-1 60.4 2718 97.78 2.22 
Sample-2 46.78 2470 98.11 1.89 
Sample-3 43.76 2726 98.39 1.61 
30 Sample-1 60.12 2223 97.30 2.70 
Sample-2 61.8 2317 97.33 2.67 
Sample-3 62.53 2536 97.53 2.47 
Sample-4 63.66 2477 97.43 2.57 
Sample-5 56.68 2620 97.84 2.16 
Mean (n =33) 97.44 2.57 
S.O. 0.22 0.22 
C.V. (0/0) 0.23 . 8.57 
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3.3: Results for recovery of propofol in plasma and in 
protein binding 
An initial isolation of · drug and metabolites in 
biological samples by means of extraction, protein 
precipitation or other procedures is usually performed 
before these samples are chromatographed to separate the 
drug, metabolites and the internal standard. Sometimes, a 
combination of multiple isolation procedures is necessary 
in order to allow adequate chromatographic separation. Many 
of these sample preparation procedures cause -a loss of the 
drugs or metabolites due to incomplete extraction, 
adsorption, volume loss or co-precipitation. It is seldom 
that the drugs can be completely recovered from the 
" 
biological samples, but the reduced recovery should be 
minimized by optimizing the conditions for the isolation 
procedures. 
3.3.1: Recovery of propofol (unheated samples) 
Recovery may be concentration-dependent and needs to 
be evaluated over the range of the expected concentrations 
in ~he samples. Pooled control plasma is spiked with a 
known concentration of propofol (3000 ng/ml). This pool is 
stored in - 70°C and then assayed for propofol content on 
Day 0, 1, 3, 5, 7, 14, 30. (6 trials each day). The 
extraction recovery results obtained for all 7 analysis 





1. 70 (described in Table 4 - 6: Recovery of propofol in 
plasma) . 
3.3.2: Recovery of propofol (samples heated at 37°C) 
The same lot of pooled plasma spiked with propofol 
(3000 ng/ml) as mentioned in the previous paragraph is 
used. This time however, the samples are heated in a 37°C 
water bath for 4 hours and then assayed for propofol 
content. This is done on three separate occasions (2 trials 
each day). The results obtained is compared with the 
results of those samples which were not heated to 37°C 
prior to propofol assay on the same analysis day. (Day 5, 
14, 30). The percentage recovery of heated (n = 2) against 
unheated (n = 6) samples is 90.64% and S.D. 0.72, 
[described in Table 4-7: Recovery of heated (37°C) & unheat 
propofol in plasma] . 
3.3.3: Recovery of propofol (after dialysis at 37°C) 
Pooled control plasma spiked with known concentration 
of propofol (3000 ng/ml) is dialysed at 37°C water bath and 
after 4 hours of dialysis, the plasma and buffer 
compartments and are then assayed for propofol content. The 
same lot of pooled samples as mentioned above is used. This 
study is done on three separate occasions (Day 5, 14, 30) 
and two trials are done per day. The percentage recovery 
results obtained for all 3 analysis days (n = 6) for 
propofol in plasma is 97.15% and S.D. 1.11 [described in 
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Table 4-8: Recovery of heated (37°C) dialysed & not 




Recovery of Propofol 
in Plasma 
Day Expect Sample Recovery 
.' 
Conc. (ng/ml) Cone. (ng/ml) (%) 
0 3000 2923 97.43 
1 3000 2882 96.07 
3 3000 2825 94.17 
5 3000 2926 97.53 
.. 
7 3000 2835 94.50 
, 14 3000 3008 100.27 
" 
30 3000 2850 95,00 
Mean (n = 42) 96.42 
S.D. 1.70 




Recovery of Heated (37°C) & Unheated 
Propofol in Plasma 
Sample Concentration (ng/ml) .- Recovery Day 
Unheated Heated (%) 
Mean (n = 6) Mean (n = 2) 
.-
5 2926 2621 89.58 
14 3008 2726 90.63 
". 
.-
30 2850 2614 91.72 
Mean (n = 6) 90.64 
S.D. 0.72 




Recovery of heated {37°C} 
Dialyzed & Not dialyzyed Propofol in Plasma 
Day Sample concentration (ng/ml) ." Recovery 
Not Dialyzed Dialyzed (%) 
'. 
Mean (n = 2) Mean (n = 5) 
" 
5 2621 2552 97.37 
14 2726 2688 98.61 
.. 
30 2614 2496 95.49 
Mean (n = 6) 97.15 
S.D. 1.11 
C.V. (%) 1.14 
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3.4: Results for stability of propofol in plasma 
In our laboratory, the samples were assayed within one 
month. Long-term storage enhances the probability of 
degradation of the drugs and metabolites in the biological 
samples. The analysis of biological samples should be 
completed before the degradation of the drugs occurs. 
Pooled plasma is spiked with known volume of standard 
Propofol to prepare pooled controls containing 3000 ng/ml. 
Aliquots of 0.7 ml of this pooled control are' transferred 
into 1.5 ml eppendorf tube and stored at 4°C to be 
subsequently assayed on separate analysis to check for 
stability during storage. The graph bases on the Table 4-6: 
Recovery of propofol in plasma (Fig 4-2: stability of 
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4: Discussions of protein binding of propofol 
4.1: optimum dialysis time to reach equilibrium 
Because ligand binding has an optimum dialysis time, 
hence the need to determine a more reliable equilibrium 
time. Based on Table 4-1: and Fig 4-1: Ligand binding 
experiments result, this optimum dialysis time is between 
120 to 210 minutes. No significant change in the amount of 
" 
bound was detected from 120 min to 210 min. We decided to 
choose 240 minutes to assure that equilibrium was achieved. 
4.2: Discussion for Intraassay & Interassay coefficient 
of variation of propofol in plasma and in protein binding 
The precision of the analysis is estimated as the 
relative standard deviation (coefficient of variation) of 
the measured concentrations of replicate samples and the 
accuracy is estimated as the percent differences (bias) 
between the mean values and true or known concentrations. 
When the analysis of the seeded control samples are carried 
out in the same assay run or on the same day the precision 
data are reported as within-day precision as compared with 
between-day precision for which the analysis is performed 
on different days. The criteria for acceptable precision 
and accuracy of the assay results cannot be generalized 
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because both precision and accuracy depend on the 
concentrations of the analyses being evaluated (Thompson 
1988) and the acceptable criteria depend on the purpose of 
the analysis. In the analysis of biological samples for 
pharmacokinetic studies, assay results with <10% relative 
standard deviation and <10% bias may be considered 
acceptable (Geoffrey & Win. 1990). 
In our method, the intraassay coefficient of variance 
of total propofol in plasma (n = 6), which was done on one 
analysis day, was 1.97% at 3000 ng/ml, and protein bound 
.' 
propofol was 0.11% and free propofol was 3.65% (described 
in Table 4-2: Intraassay coefficient of variance for 
propofol in plasma & Tab~e 4-3: Intraassay coefficient of 
variance for propofol in protein binding). The interassay 
coefficient of variation of total propofol in plasma (n = 
42) was 2.19% at 3000 ng/ml (described in Table 4-4: 
Interassay coefficient of variance for propofol in plasma) , 
protein bound propofol was 0.23% and free propofol was 
8.57% (described in Table 4-5: Interassay coefficient of 
variance for propofol in protein binding). The assay 
results may be considered acceptable. 
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4.3: Recovery of propofol in plasma and in protein 
binding 
Recovery should also be reproducible. An assay method 
with low but reproducible recovery may be acceptable when 
" 
the samples are analyzed with appropriate calibration 
st~ndards. In some literature reports, the concentration of 
drug found in seeded control samples expressed as the 
percentage of the known drug concentration is called 
IIrecoveryll. 
Like precision and accuracy, recovery may be 
concentration-dependent and need to be evaluated over the 
range of the expected concentration in the samples. 
However, good precision and accuracy cannot be obtained 
when the recovery of the analyses is not reproducible. 
In some literature repo~ts, the concentration of drug 
found in seeded control samples expressed as the percentage 
of the known drug concentration is called IIrecovery". By 
this definition, recovery is the same as accuracy and this 
is reason that accuracy is reported as IIrecovery" by some 
analysts. As defined, the recovery should be close to 100%. 
However, recovery · experiments are usually done when the 
assay method is being developed or validated. The purpose 
is to obtain an overall high recovery of drugs, preferably 
>75%, from the samples taken through the complete 
analytical procedures. Accuracy, on the other hand, is 
continuously monitored as the samples are analyzed. 
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In our method, The extraction recovery results 
obtained for all 7 an~lysis days (n = 42) for propofol in 
plasma is 96.42% and S.D. 1.70 (described in Table 4-6: 
Recovery of Propofol in Plasma). 
This .time however, the samples are heated in a 370C 
water bath and then assayed for propofol content. The 
results obtained is compared with the results of those 
samples which were not heated to 37°C prior to propofol 
assay on the same analysis day. The percentage recovery of 
heated (n = 2) against unheated (n = 6) samples is 90.64% 
and S.D. 0.72, (described in Table 4-7: Recovery of heated 
(37°C) & unheat propofol in plasma). Between Table 4-7: 
Recovery of heated (37°C) and unheated propofol in plasma 
and Table 4 -8: Recovery of heated (37 ° C) dialysed and 
undialysed propofol in plasma, the difference between the 
results from the two tables is only 6.51%. However, this 
does not produce a significant effect on the outcome of the 
ligand binding experiments as shown in Table 4-1: Ligand 
binding results, whereby the total propofol content (buffer 
+ plasma) does not change significantly any more after 120 
minutes. 
-Propofol (3000 ng/ml) is dialysed at 37°C water bath 
and after 4 hours of dialysis, the plasma and buffer 
compartments and are then assayed for Propofol content. The 
same lot of pooled samples as mentioned above is used. The 
percentage recovery results obtained for all 3 analysis 
days (n = 6) for propofol in plasma is 97.15% and S. D. 
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1.11, (described in Table 4-8: Recovery of heated (37°C) 
dialysed & not dialysed propofol in plasma) . 
Above results of recovery may be acceptable, because 
the recovery close to 100%. 
4.4: Discussion for stability of propofol in plasma 
stability of plasma samples are checked by assaying 
aliquots of a pooled control on separate analysis days (n 
= 8 up to 1 months for plasma). No significant decrease in 
the amount of Propofol was detected throughout the course 
of the stability studies. (Fig 4-2: stability of propofol 
., 














































































































































































































OF PHARMACOKlNETIC STUDIES 
1: Introduction pharmacokinetic model controlled infusion 
The following infusion study is an example of the 
application of our method of analysis in children: A 
prospective eva~~ation of pharmacokinetic model controlled 
infusion of propofol in paediatric patients (Short et aI, 
" 
1994) • 
1.1: Theoretical basis 
The disposition of infused propofol is assumed to be 
described by an equation representing a three-compartment 
model, with drug entering or leaving the system only by the 






Fig. 5-1: The three-compartment pharmacokinetic model 
where VII V21 . and V3 represent the volumes of distribution. 
" 
is the initial volume of distribution. The 
intercompartmental and elimination rate constants are 
shown. 
The blood concentration = concentration in the central 
compartment (Vd· 
Initially, all compartments have propofol 
concentrations of zero. To achieve the target blood 
concentration rapidly (volume 1 concentration) I sufficient 
drug is given as an initial bolus dose. 
" 
Dose or Al = eTa * V * wt 
If the blood concentration (i.e. that in volume 1) is to be 
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kept constant, the amount of drug entering it and leaving 
it must be equal. Drug leaves the blood to pass into 
volumes 3 and volumes 2 at a gradually decreasing rate as 
the concentrations in these compartments increase. ·Drug 
also leaves the blood because it is metabolized, given by 
(klO * volume 1) ml/min. 
If we consider only the transfer of drug from one 
compartment to an adjacent compartment, the rate of drug 
transfer equals the amount of drug in the source 
compartment times a rate constant, k, to which we append 
a subscript indicating which compartment i~· involved. Of 
co~rse, drug is transferring in the opposite direction as 
well at a rate that equals the amount in adjacent 
compartment times a different rate constant. The net rate 
of change in drug . concentration in a compartment is the 
rate at which the drug is entering the compartment, less 
the rate at which the drug is leaving the compartment. 
Theoretically, it would take an infinite time for the 
·peripheral compartments to achieve the target 
concentration . For the slowest compartment to achieve at 
least 94% of any target concentration, it could take 
approximately 16 hours (Tackley et aI, 1989). Finally, when 
there is no further redistribution to other compartments, 
the amount of drug to be infused would be equal to that 
being cleared. 
The rate of change in each compartment for a 3-
121 
compartment model can be described with the following 
equations (Maitre & Shafer, 1990). 
Where A2/ dt = Alk12 - A2k21 
A3/ dt = Alk13 - A3k31 
where AI' A2, and A3 are the amount of drug in compartments 
VI' V2, and V3, respectively. These equations cannot be used 
directly by a calculator, because dt is an infinitely 
small time interval. However, we can approximate these 
equations by substituting ~t for dt, and assigning a small 
time interval, (e.g., 10 s), to ~t. This is known as 
"Euler's" Numeric · Integration technique. We can thus 
approximate . the change in drug concentration in each 
compartment with the following equations: 
Equation (2) can be easily modified to account for a bolus 
injection (amount = B) and a continuous infusion (rate = R) 
of drug to the central compartment: 
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Thus a pseudosteady state concentration can be maintained 
in VI' the central compartment. Re-write the equation for R, 
~th~n you have the infusion rate by pharmacokinetic model 
controlled or 
(4) 
Where AI' is the next value of A. 
1.2: Use of computer & appropriate pump 
Thepropofol dose required to maintain the desired 
plasma concentration was delivered using an Ohmeda 9000 
infusion pump controlled by a 386SX IBM compatible laptop 
computer connected via an Rs232C serial interface. A 
program was written in 'C' (Turbo C, Borland, USA) to 
control the -pump (by Y.H. Tam). 
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2: Results of propofol pharmacokinetic studies 
2.1: Sample preparation 
Permission to conduct the study was obtained from the 
Research Ethic committee of the Faculty of Medicine of the 
Chinese university of Hong Kong, and informed consent were 
obtained from the children's parents. Ten patients aged 
from 4 to 8 years were studied. All were healthy (ASA I) 
had been full term babies, had no contra indications to the 
drugs used in the trial and were undergoing minor surgical 
procedures associated with minimal blood loss. Patients 
with preoperative haemoglobin level less than 11.5 gjdl 
were excluded. All the operations were performed in the 
operation theatres of the Prince of Wales Hospital, 
(Shatin, New Territories, Hong Kong). EMLA Cream 5% (2.5% 
lignocaine and 2.5% prilocaine, Astra Pharmaceuticals, 
Sweden) was·· applied to the dorsum of one hand one hour 
preoperatively to assist with intravenous catheter 
placement. Anaesthesia was induced with intravenous 
propofol given by an infusion pump and maintained using the 
pr~pofol infusion and nitrous oxide 70% in oxygen. All 
patients breathed spontaneously. The propofol infusion 
model used was similar to that of Marsh et aI, 1991. The 
system consisted of an Ohmeda 9000 syringe pump controlled 
by ·a .j86SX IBM compatible computer via an RS232C serial 
-interface. After having purged the intravenous tUbing using 
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the purge option on th~ pump, an initial bolus of propofol 
was giv~n according to body weight at the pump's top rate 
(1200, ml/h) to rapidly attain the desired plasma 
concentration. The infusion rate was then adjusted by the 
computer to maintain the desired plasma concentration using 
a three compartment pharmacokinetic model. The target 
plasma concentration was adjusted up or down in 1-2 ~g/ml 
steps as according to standard clinical criteria, including 
movement in response to pain, respiratory cardiovascular 
and sympathetic nervous system signs. Time from switching 
off the infusion until eye opening in response to verbal 
command was recorded (Short et al. 1994). 
A second intravenous catheter was placed in a large 
vein in the oppcsite limb to that used for the propofol 
infusion. It was used for taking venous blood samples for 
later analysis of blood propofol concentrations. Two ml 
blood samples were drawn at the time of surgical incision 
and then at approximately ten minu~es intervals during the 
procedure. Up to four samples were also taken in the 
recovery room during the first hour following termination 
of the infusion. A maximum of eight blQod samples were 
taken from each patient (Short et al. 1994). Blood samples 
were collected into a 5 ml heparinized tube and stored at 
40C for ' later analysis using high-pressure liquid 
chro~at?graphy with fluorescence detection. (as described 
in Chapte~ Three 2: Methods for propofol content analysis) 
Analysis of whole blood concentrations propofol (Cp) 
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was performed. For ~pecimens with expected propofol 
concentrations above 3000 ng/ml dilution was used to 
decrease propofol concentration to within the calibrated 
range of the assay (detail describe as above Chapter Three: . 
3: Calibration standard of propofol). 
2.2: computer control infusion of propofol according to 
pharmacokinetic model 
Fig 5-2: illustrates the course of a typical 
anaesthetic administered to a 18.7 kg child (aged 5 years) 
undergoing circumcision using the computer aided infusion 
device. In this study we prospectively tested the use of a 
previously published algorithm for administering propofol 
to paediatric patients (Marsh. et al. 1991). Anaesthesia was 
induced by selecting an initial theoretical target 
concentration of 10 ~g /ml. Thereafter, the target was 
reduced to 6.00 ~g/ml without deterioration in the 
operating conditions, and then the target concentration was 
titrated according to the depth 'of anaesthesia required. 
The anaesthesist retained at all times the option of 
increasing or decreasing the theoretical target blood 
concentration according to his or her clinical impression 
of the quality of anaesthesia. At the termination of 
surg~ry~ the pump was switched off and the patient 
transferr~d to the recovery room, where the device 
calculated the theoretical decay of propofol concentration 
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in the patient's blood, until eye opening was observed. In 
Fig 5-2:, the measured values of blood propofol were 
overlaid on the system record of the theoretical propofol 
. profile and it could be seen that, in this individual, the . 
delivery system consistently overpredicted the measured 
blood concentration of propofol. 
Fig 5-2: Predicted and measured blood concentrations 
of propofol during anaesthesia in a 18.7 kg patient (Age 5 
years). The solid line represents predicted v~lues, 
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2.3: comparison of me~sured and predicted blood 
concentrations of propofol 
Throughout the study, measured blood concentrations of · 
propofol (Cp) were compared with the corresponding delivery 
sy~tem predicted value. The prediction error was calculated 
for each data point, this' being defined as (Glass et aI, 
1989) • 
Prediction error 
Cp (measured) - Cp (predicted) 
= x 100 
Cp (predicted) 
Bias was defined as the mean prediction error and is 
taken in these " circumstances to be a measure of the 
systematic tendency of the system to under or over-estimate 
the ' measured concentration of blood propofol. That is to 
say, if bias has a positive value, then the measured value 
is , on average, greater than the system prediction and 
vice versa. Precision is defined as the mean value of the 
sum of individual absolute values of prediction error and 
is a measure of the degree of scatter of the data about the 
line of perfect prediction. A two stage approach was used, 
because of the different numbers of blood samples taken 
from each · patient. Bias and precision were calculated for 
each .. pa.tient and then the population bias & precision 
calculated. 
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Precision (average absolute error) and bias (average 
error) ware calculated for each individual data set using 
the following equations: 
n ~-~ n ~-~ E E 
j=l Yj j=l ~ 
precision = bias = 
n n 
Where 
n = number of measured propofol levels for each patient. 
Y = measured blood propofol conce~tration. 
9 = predicted blood concentration. 
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. ; . . ._- _._.,--.;.... 
Fig. 5-3: comparison of percentage prediction error 
., 




Fig. 5-4: comparison of measured and predicted blood 
concentrations of propofol for the first study population 
(n~67, r~O.89). The dashed line is the line of identity 
(y=x) (~ased on Short et al. 1994) 
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Table 5-2: Comparison between the Marsh's propofol 
infusion model and revised rate constants for propofol 
using a three compartment open model, and comparison of 







1st Group 2nd Group 
-----------------------------------------------------------
Vc (ml/kg) 343 432 432 
k10 /min) 0.1000 0.-0967 0.0967 
k12 /min) 0.0855 0.1413 0.1413 
k13 /min) 0.0210 0.0392 0.0392 
k21 /min) 0.0330 0.1092 0.1092 





(-41 to 10) 
24.26 
(7 to 41) 
-0.06 
(-28 to 29) 
22.81 
(8 to 32) 
0.19 
(-30 to 42) 
21.06 
(8 to 43) 
-----------------------------------------------------------
1st Group: Table 5-1: The result of propofol infusion for 
Chinese children (first group) 
2nd Group: Table 5-3: The result of propofol infusion for 
Chinese children (second group) detail in follow 2.4: 
Test the new paediatric pharmacokinetic model. 
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Blood concentration for satisfactory anaesthesia 
ranged from 5-13 ~g/ml. Mean total dose of propofol given 
was 372 mg (range 263-563 mg) and the mean rate of infusion 
. was 29.8 mg/kg/h. The population mean prediction error 
(bias) was calculated to be -17.88% and the corresponding 
value for precision obtained was 24.26%. After linear least 
squares regression the revised rate constants had a 
precision of 22.81% and bias of -0.06% (Table 5-2: Revised 
rate constants: Vc = 432 ml/kg, klO = 0.0967/min, k12 = 
0.1413/min, k13 · = 0.0392/min, - k21 = 0.109.2/min, k31 = 
0.0049/min). Fit of the mo~el was significantly improved (p 
< 0.001). using a paired t test to c6mbine each individual 
mean for Bias & Precision. (Short et at. 1994) 
In the first study, each measured blood value of 
propofol was compared with its corresponding delivery 
system prediction and the results obtained were displayed 
in Table 5-1: The results of propofol infusion for Chinese 
children (first group). The~e results were plotted in the 
form of prediction error vs predicted concentration (Fig 5-
3: comparison of percentage prediction error and predicted 
concentration. n = 67). It may be seen from this figure 
that the majority of the data points lie below the line of 
zero prediction error (the line of perfect prediction). 
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2.4: Test the new paediatric pharmacokinetic model (the 
revised paediatric rate constants) . 
In order to test the new paediatric pharmacokinetic 
model prospectively, a second study was performed in the 
patients in second group [Table 5-3: The result of propofol 
infusion for Chinese children (second group)] In this 
second study, the computer controlled propofol infusion 
system was programmed with the revised paediatric rate 
constants. As before, measured blood concentrations of 
propofol were compared with their corresponding predicted 
values calculated by the delivery system algorithm. Fig 5-
5: (Comparison of measured and predicted blood 
concentrations gf propofol for the second study population) 
shows the relationship between measured and predicted 
values for the entire prospective study population and Fig 
5-6: (Comparison of percentage prediction error and new 
predicted value using the newly derived paediatric 
pharmacokinetic parameters for propofol n = 172) shows the 
distribution of prediction errors in relation to their 
predicted values. The bias of the revised rate constants 
delivery system was calculated to be 0.19% and the 
corresponding value of precision was 21.06%. It can be seen 
that, prospectively, the revised paediatric rate constant 
system gave a relationship between measured and predicted 
values of blood propofol which was superior to that 
obtained using the rate constants system based on the 
136 
paediatric data estimated by Marsh & colleagues used in the 
initial study. It also compared closely to the relationship 
predicted by computer simulation using the revised 
paediatric rate constant system. 
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INFUSION.XL2 
Table 5"-3 I I I I 
The result of Propofol infusion 
for Chinese children (second group) 
Vc K10 K12 K13 K21 K31 
(litre/kg) (/min) (/min) (/min) (/min) (/min) 
Revised rate constants 0.4320 0.0967 0.1413 0.0392 0.1092 0.0049 
Patient's Sex Age weight Drug Revised rate constants 
Name (kg) (mg) Error Absolute error Square error 
Pinfu-11 M 4 16.7 270 2.27 16.56 1505740 
Pinfu-12 M 6 20.3 408 -10.96 10.96 326121 
.' 
Pinfu-13 F 9 33.0 736 7.89 14.66 1014033 
'. 
Pinfu-14 M 10 25.0 797 8.26 13.99 1233897 
Pinfu-15 M 8 18.8 344 24.86 24.86 602237 
Pinfu-16 M 5 18.8 537 -13 .74 18.16 1892876 
Pinfu-17 M ., 6 17.1 321 -5.29 12.34 387495 
Pinfu-18 M 6 19.4 376 23 .36 24.23 3488355 
Pinfu-19 M 6 24.5 271 -17.20 20.28 449052 
Pinfu-20 M 4 16.5 222 6.23 16.01 1268514 
Pinfu-21 , M 9 29.7 419 -0.35 16.93 869385 
" 
Pinfu-22 M 4 15.3 171 -19.56 23.56 904747 
Pinfu-23 M 9 23.3 410 -17.73 18.52 828588 
Pinfu-24 M 10 27.0 377 -21.30 34.27 2590242 
Pinfu-25 M 9 43.7 797 42.44 43.09 3393649 
Pinfu-26 M 4 16.3 302 -30.47 30.47 3321115 
Pinfu-27 M 5 19.6 299 1.54 8.41 320370 
" 
Pinfu-28 M 6 23.6 314 15.08 22.67 2322222 
Pinfu-29 M 9 39.0 623 22.44 30.84 3428072 
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Fig. 5-5: comparison of measured and predicted blood 
concentrations of propofol for the second study population. 
The predicted values were derived by weighted least squares 
regression using the derived paediatric pharmacokinetic 
parameters for propofol (n=172). Dotted line represents the 










4 6 8 10 12 
Predicted 0lg.ml-l) 
Fig. 5-6: . comparison of percentage prediction err~r 
and new predicted value obtained by pharmacokinetic 
simulation using the derived paediatric pharmacokinetic 
parameters for propofol (n=172) (Based on Short et al, 
1994) • 
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3: Discussion of propofol pharmacokinetics studies: 
infusion for Chinese children 
In this study we have evaluated prospectively a 
pharmacokinetic model-driven infusion of propofol based on 
that of Marsh and colleagues (Marsh et al. 1991). This 
model had been developed using children of similar age and 
undergoing similar procedures to the patients in this 
study. Its accuracy had been conf irmed by prospective 
testing. When compared with their data, in our patients the 
.' 
precision model was lower (24.26% vs 22.81%' , 21.06%) and 
there was a large negative bias: the algorithm 
underestimated blood concentrations by 17.88%. (described 
as Table 5-2: Comparison between the Marsh IS propofol 
infusion model and revised rate constants for propofol 
" 
using a three compartment open model, and comparison of 
bias and precision). This indicated that the 
pharmacokinetic data of Marsh and colleagues were not 
applicable to our patients. Therefore, we revised the 
pharmacokinetic variables and tested the new variables 
prospectively, when they were found to fit our population 
well~ This confirms the difference in the pharmacokinetic 
profiles of the children in the two studies (Short et al. 
1994) . 
The reasons for the difference in pharmacokinetic 
variables between the present study and that of Marsh and 
colleagues (Marsh et al. 1991) are unclear. The main 
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differences between the two studies were that our study was 
of Chinese children and our anaesthetic technique did not 
include sedative premedication. Analgesia in the form of a 
local anaesthetic block was also performed at the end of 
surgery rather than at the beginning, in the first phase of 
the study. However, although the change to performing the 
local anaesthetic block before surgery for the second part 
of the study reduced propofol requirements, it did not 
alter significantly the pharmacokinetic profile of 
propofol. The volume of distribution of the central 
compartment in our model was 25% larger than that of Marsh 
and colleagues and is close to the value obtained in a 
previous pharmacokinetic study of a bolus dose of propofol 
in Chinese children (Jones et al. 1990). However, caution 
must be exercised in interpreting the pharmacokinetic 
variables in the model after it has been subjected to an 
iterative least squares regression procedure, because the 
relative contr~bution of each variable to the overall model 
is influenced by its order in the regression procedure. The 
revised model is regarded best as a mathematical algorithm 
that best fits the blood concentration-time profile of the 
drug, rather than a true compartmental pharmacokinetic 




ON PROTEIN BINDING STUDIES 
1: Plasma proteins and drug binding 
The pharmacological response _obtained is, for the 
majority of drugs, related to the concentration of drug at 
its receptor ~ite(s). The disposition and ultimate 
biological effect" of the drug may be said to be 
'influenced' by the extent of plasma protein binding. Any 
significant alteration in plasma protein binding can lead 
to an altered drug distribution and unexpected 
pharmacological responses. A change in protein binding also 
has implications for therapeutic drug monitoring. 
Human plasma contains over 60 different proteins. 
PlGlsma albumin is the most abundant protein in plasma, 
accounting for approximately 50% of total proteins. It 
exerts 80% of the colloid -osmotic pressure of blood and is 
therefore an essential factor in the maintenance of blood 
volume. The interaction between proteins and drugs is 
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governed by the law of mass action. Plasma protein binding 
of drugs is usually reversible (the half-life tin being in 
the order of milliseconds) and, generally, changes in 
protein binding only cause significant clinical effects for 
drug that ,are highly protein bound because it is the free 
drug that exerts the effect. A 1% decrease in binding 
capacity for a drug that is normally 99% bound to plasma 
proteins would have the effect of doubling the 'free' drug 
available for distribution and metabolism. The principal 
plasma proteins involved in drug binding are albumin, 
glycoproteins and lipoproteins. 
There are changes in protein p~sition in children and 
also in pregnancy and several studies were performed to 
determine whether there were any changes in protein binding 
in~these population. 
2: Methods of propofol protein binding studies 
2.1: Blood sample acquisition 
. The studies was approved by the Clinical Research 
Ethical Committee and informed consent was obtained from 
all patients or volunteers. Patients selected were healthy 
(ASA I or I1). Venous blood was collected into a 
heparinized tube and sent immediately to the laboratory for 
propofol protein binding study (level 2000-3000 ng/ml). 
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2.2: population characteristics 
Venous blood was taken from 6 groups of sUbjects. 
A. Non pregnant, pre-menopausal women, who were not taking 
hormonal contraceptives. 
B. - ~Patients scheduled for elective Caesarean section at 38-
42 weeks gestation. 
C. Umbilical venous blood obtained from the placenta after 
elective Caesarean section at 38-42 weeks gestation. 
D. Children between 1-3 years. 
E. Children between 3-12 years. 
F. Adults 18-40 years. 
2.3: Methods of protein binding assay 
Refer to Chapter Four: 2: Methods of protein binding 
of propofol for details on protein binding assay. 
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3: Results of propofol protein binding 
The res'ults of propofol protein binding described in 
Table 6-1: The result of propofol -protein-binding study 
(Children & Adult), Table 6-3: Population characteristics 
in propofol protein-binding (Children & Adult), and Table 
6~~: The result of propofol protein-binding study (Pregnant 
& Neonate), Table 6-4: Population characteristics in 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































in propofol protein-binding 
(pregnant & Neonate) 
." 
Groups Protein-Binding (%) 
" 
" 
of patients n "Mean S .D. ' c.v.(%) 
, " 
pregnant 19 98.60 0.27 0.28 
Neonate 17 96.58 0.53 0.55 
Non-pregnant 16 98.92 0.25 0.25 
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4: Discussion of propofol protein binding 
The binding of drugs to proteins, especially plasma 
proteins, can have . a marked influence on their 
pharmacokinetics and pharmacodynamics and, therefore, on 
therapeutic drug monitoring. Nonprotein bound drug is the 
portion best correlated with pharmacologic activity and the 
pharmacokinetic characteristics of the total drug. Plasma 
and tissue protein binding is intimately involved in 
determining a particular drug's volume of distribution, 
transport to and from the site of action or degradation, 
and elimination from the body. Disease states, concomitant 
drug therapy, genetic, and age-related factors can alter 
the extent and affinity of protein binding and thus affect 
the pharmacokinetic important free drug concentrations. 
Propofol analysis normally measures total (free + bound) 
drug, and any alteration in the free:bound drug ratio may 
have implications iri calculation of the dose. Therefore, a 
knowledge of the conditions under which changes in the 
plasma protein binding of drugs occur, and the extent of 
those changes, is valuable in predicting response and 
possible dose adjustment. 
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4.1: Protein binding of propofol in Chinese children 
Children have been shown to require a larger dose of 
propofol than adults (Aun et ai, 1992). Propofol is highly 
protein bound (97% - 99%), in young children « 3 years 
old), we find the value has a highly protein-binding for 
propofol [98.77 ± 0.29 % (mean ± S.D.)], and the older 
children (3-12 years old) has also highly protein-binding 
[98.69 ± 0.33 % (mean ± S. D. )] [described in Table 6 -3 : 
population characteristics in propofol protein-binding 
(Children & Adult)]. Compared the young children & children 
with adult [98.35 ± 0.29 % (mean ± S.D.)] [described in 
Table 6-3: population characteristics in propofol protein-
binding (Childr.en & Adult)]. It show no significant 
difference in the propofol protein-binding between children 
and adult, using an unpaired t test. The propofol protein 
binding analysis study therefore suggests that the 
difference in the dose requirement between children and 
adults was not due to the differences in protein binding 
(unpublished data from Aun et ai, 1994). 
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4.2: Protein binding of propofol in Pregnant women & 
neonate 
Changes in the composition of maternal plasma/serum 
during normal pregnancy are now well documented. As well as 
a quantitative change in the normal proteins, there occurs 
during gestation synthesis of plasma proteins which are not 
normally detected in non-pregnant women. In addition there 
are changes in plasma concentrations of free fatty acids, 
hormones and other endogenous ligands, as well as large 
changes in body composition that may affect drug binding 
and ultimately response. There is an overall fall in the 
level of total plasma proteins during pregnancy, 
approximately 7% "decrease at 6 months' gestation and some 
12% at term (Haram et al. 1983). The degree of change 
recorded varies between investigators, in that some report 
a continuous reduction of total protein during pregnancy 
(Reboudet al. 1963). The level of albumin falls during 
gestation, as a result of the increase in plasma volume. In 
pregnancy, total body water increases by up to 8 L, of 
which 80% is extrcellular water. Plasma volume increases by 
40 to 50%. This increase in plasma volume represents ·1.2 to 
1~5 L, adding considerably to the normal plasma volume of 
2.5 L . 
. Neonatal drug disposition varies from that in adult 
and older infants as a result of differences in body 
co·mpos~tion, metabolism, kidney function, etc. C~anges also 
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occur in plasma composition which affect the plasma protein 
binding of drugs and the fraction of free drug. At birth a 
full-term infant has a significantly lower plasma albumin 
, level than adults, and therefore correspondingly fewer drug 
binding sites. since the amount of propofol bound is 
related to the total albumin, there may be altered 
disposition in the neonate. The major protein detected in 
the newborn during the first 3 weeks of life is a-Feto-
protein which has a lower affinity for drugs than 'adult' 
albumin (Miyoshi et al. 1966f. As the f .etal protein 
disappears from the circulation it is 'replaced' by 
albumin. The rapid decline of this protein, with . its 
altered binding, may explain the rapidly changing 
pharmacokinetics ~ ' of some drugs over the first 2 to 3 weeks 
of life. 
Pregnant patients had increased free propofol, (1.41 
± 0.30%,mean ±S.D.) compared with nonpregnant patients, 
(1.08 ± 0.26%, P = 0.004). Although these findings would 
imply that the total propofol concentration of propofol, 
and hence the dose, could be reduced in pregnant patients 
for a given effect, changes in pharmacokinetics during 
pregnancy (Gin et ai, 1991) and the increased total body 
weight in pregnancy could also affect dose requirements. 
Th~se results indicate that further simultaneous 
pharmacodynamic/pharmacokinetic modelling would be useful 
to determine the clinical signifi6ance of the changes in 
protein binding. 
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Free propofol in umbilical plasma (3.40 ± 0.61%, mean 
± S.D.) was greater than that in-maternal (pregnant) plasma 
(1.41 -± 0.30%, P = 0.001). These results are consistent 
with the umbilical: maternal ratio of propofol found at 
ca~sarean section (Gin et aI, 1991). However propofol is 
bound to red blood cell as well as albumin. The different 
composition of umbilical blood compared with maternal blood 
could also influence the protein binding and free fraction 
of propofol. The clinical significance of free propofol, 
compared with other anaesthetic agents, has not been 
evaluated. However, propofol concentrations in umbilical 
. blood at Caesarean section are relatively low, neonatal 
outcome is not worse that that after other induction 
agents, and neon~tal elimination of propofol is probably 
faster that that of thiopentone (Gin et aI, 1991). At 
present, the manufacturers of propofol do not recommend its 
use in obstetric or neonatal anaesthesia. Thus it is not 





Propofol is a commercially available intravenous 
anaesthetic agent. The main feature of propofol is rapid 
recovery from anaesthesia whether given as a bolus for 
induction of anaesthesia or by infusion to maintain 
anaesthesia. 
I have been .. able to develop two analytic methods for 
the assay of propofol: high pressure liquid chromatography 
analysis for propofol quantitation and equilibrium dialysis 
for separation of propofol in whole blood into free and 
protein bound fractions. The methods permit the 
determination of propofol in whole blood and plasma o~er a 
wide range of concentrations. 
"High pressure liquid chromatography has become the 
most popular chromatographic method, because HP~C allows 
small samples to be used, "especially with low dead volume 
detectors coupled with strip chart recorder. The 
". 
combination of HPLC and fluorescence detection has improved 
tne sensitivity of propofol measurements. The method 
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described in this thesis is more rapid and simpler to use 
than the indophenol procedure and has an improved limit of 
quantification of 2 ng/ml. The reversed phase HPLC method 
used was simple, sensitive, and reliable. The assay ' 
involved a single extraction of the drug and internal 
standard, thymol, from blood buffered with 0.1 M sodium 
", 
dihydrogen phosphate and extracted into cyclohexane. The 
organic extract, basified with tetramethylammonium 
hydroxide-, was evaporated to dryness at 37°C 'under 
nitrogen. The residue was r~diss6lved in 80 ~l. acetonitrile 
and an aliquot of the concentrate was injected into a C18 
, reversed-phase column. The mobile phase consisted of 66% 
(v/v) acetonitrile in Milli-Q water containing 1% v/v 
acetic acid and ~~s eluted at 1.7 ml/min. The components of 
the column effluent was monitored by a fluorometric 
detector with excitation and emission wavelengths set at 
276 nm and 310 nm, respectively. The method uses only 0.5 
ml of sample and this facilitates ·pharmacokinetic studies 
of propofol in children (The method was based on that 
published by Chan & So 1990). The between batches 
coefficient of variance were 9.7850 % at 50 ng/ml and 
7.6469 % at 3000 ng/ml. The intraassay coefficient of 
variation of propofol' in whole blood was 6.24% at 100 ng/ml 
and 6.10% at 500 ng/ml, while the interassay coefficient of 
variation was 3.18% at 100 ng/ml and 1.81% af 500 ng/ml. 
The extraction recovery results obtained for propofol in 
whole blood are 104% at 100 ng /ml and 99% at 500ng/ml. 
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Precision & accuracy and extraction efficiency of 
analytical method are all acceptable. A slight decrease in 
the a'mount of propofol was detected after 30 days.. The 
results of propofol assay in plasma are similar to propofol . 
assay in whole blood. 
Equilibrium dialysis was performed using a spectrum 
equilibrium Dialyser. Drug-containing plasma samples or 
protein solutions (1 ml) were dialysed against drug-free 
Sorensen I s phosphate buffer (1 ml; pH 7.4.) in teflon 
dialysis chambers separated by . Spectra/Po"r dialysis 
membrane. The teflon cells rotate at 15 rpm at 37°C. The 
optimum dialysis time was 240 min. Propofol concentration 
in samples were assayed by the HPLC method described above. 
The intraassay coefficient of variation of total propofol 
in plasma was 1.97% at 3000 ng/ml, protein bound propofol 
was 0.11% and free propofol was 3.65%. ' The interassay 
coefficient of variation of total . propofol in plasma was 
2.19% at 3000 ng/ml, protein bound propofol was 0.23% and 
free propofol was 8.57%. The extraction recovery results 
obtained for propofol in plasma are 96.42% for unheated 
samples, 90.64% for samples heated at 37°C, and 97.15% for 
samples dialysised at 37~C in a water bath . 
. On~ application of my research was the ' prospective 
testing in chinese children of a previously published 
pharmacokinetic model driven algorithm for computer 
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controlled infusion of propofol. The concept of computer 
controlled infusion devices to deliver i. v. anaesthetic 
drugs ' according to pharmacokinetic model-driven algorithms 
is attractive. Drugs may be administered to a theoretical · 
target blood concentration calculated by the algorithm. All 
relevant pharmacokinetic data are contained in the 
algorithm implying that administration of the infusion is 
simplified and there is no need to remember formulae for 
delivering the infusion by manual adjustment. Successful 
use of these algorithms requires a knowledge of blood 
concentration-effect relationships for the drug and of the 
accuracy of the algorithm. In this study we tested 
prospectively the use of an algorithm published previously 
" 
for administerin'g propofol to paediatric patients with 
precision of 24.26% and bias of -17.88%. The model was 
revised using an iterative linear least squares regression 
and minimizing total mean squared prediction error for each 
patient. The precision-. of the ' revised model was 21.08%, 
bias was 0.19%, and the fit of the model was significantl~ 
improved (p < 0.001). 
Another application of my research was to investigate 
protein binding of propofol in different populations 
because pharmacological response to drugs is influenced by 
th~ ,free fraction of drug. Propofol protein hinding was 
estimated- by equilibrium dialysis, to be 97-99% bound in 
children and adults. From 'our studies, young children « 3 
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years old) have protein-binding of 98.77 ± 0.29% (mean ± 
s. D. ), children 3-12 years old have protein-binding of 
98.69 ' ± 0.33%, and adult have protein-binding of 98.35 ± 
0.29% . 
• , Pregnant patients had increased free propofol, 1.41 ± 
30% compared with nonpregnant patients, 1.08 ± 0.26% (p = 
0.004). These findings indicate that further simultaneous 
pharmacodynamic/pharmacokinetic studies would be useful , to 
determine the clinical significa-nce of changes in protein 
binding. Free propofol in umbilical plasma 3.40 ± 0.61% was 
grea~er than that in maternal (pregnant) plasma (p = 
0.001). The clinical significance of free propofol in 
neonates, compared with other anaesthetic agents, has not 
been evaluated. However, propofol concentrations in 
umbilical blood at Caesarean section are relatively low, 
neonatal ' outcome is not worse that that after other 
induction agents, and neonatal elimination of propofol is 
probably faster that that of thiopentone. At present, ,the 
manufacturers of propofol do not recommend its use in 
bbstetric or neonatal anaesthesia. Thus it is not likely 
that further studies will be carried out at this time. 
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CH3CN HPLC Grade, MERCK Art 2856, E. Merck, Frankfur, 
Germany. 
Acetic acid 
CH3COOH glacial 100% Guarantee grade, MERCK Art 2500, 
E. Merck, FrankfuF, Germany. 
centrifuge 
BECKMAN CPR centrifuge, BECKMAN Instruments INC, 
Fullerton, California, U.S.A. 
Column Nova-pak C18 aDS 
Waters division of MILLIPORE, Milford, MA, U.S.A. 
cyclohexane 
CH2 • (CH2)4.CH2=84.16 AnalaR UN 1145, BDH Limited, Poole 
Dorset, England. 
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ni-sodium hydrogen phosphate 
Na2HP04 .2H20 11.87 g/L M=13T.99 g/mol guarantee grade, 
MERCK Art 6586, E. Merck, Frankfur, Germany. 
Fluorescence spectrophotometer 
- 650-40 model, HITACHI LTD, Tokyo, Japan. 
Hydrochloric Acid 
C (HCl) =1 mol/L (IN) Volumetric solution MERCK, Art 
9057, E. Merck, Frankfur, Germany. 
Injection system 
RHEODYNE COTARI 7010 Modle, RHEODYNE INCORPORATED, 
Cotat, California, U.S.A. 
Integrator 
HP 3396A HEWLETT PACKARD Company, Atlanta, Georgia, 
U.S.A. 
Metering pump 








Tap' water through the Mill-Q Reagent water system. 
MILLIPORE corporation, Bedford, MA, U.S.A. 
Mixture 
THERMOLYNE speci-Mix SYBRON Corporation, Dubuque, 
Iowa, U.S.A. 
", 
Molecularporous Dialysis Membrane 
Spectra/Por, SPECTRUM MEDICAL IND., INC, Los Angeles, 
California, U.S.A. 
Ohmeda 9000 syri~ge pump 
Ohmeda, West Yorkshire, U.K 
PH-Meter 
CG 804 SCHOTT-GER' A'TE GmbH, Postfach, Hofheim a. Ts., 
Germany. 
Potassium . dihydrogen phosphate 
KH2P04 9.073 g/L M=136.09 g/mol Guarantee grade, MERCK 
Art 4873, E. Merck, Franfurt, Germany. 
2-Propanol (IPA) 
Guarantee grade, ' MERCK Art 9634, E. Merck, Franfurt, 
Germany. 
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Propofol stock solutions 
ICI Pharmaceutical Division, 35,868. Macclesfield, 
Cheshire, England. 
Rotary tumbler 
CHILTERN, SMITH BIOLAB LTD., Auckland, New Zealand. 
Screw-cap glass tube 
PYREX IWAKIGLASS, IWAKI GLASS Co, LTD., Chi yda-Ku 
Tokyo, Japan. 
Sodium dihydrogen phosphate 
NaHzPOc • HzO 0 .1M M=137. 99/mol. Guarantee grade, MERCK 
Art 6346, E. Merck~ Frankfurt, Germany. 
Sodium hydroxide solution 
C(NaOH)=l mol/L (IN) Volumetric solution MERCK Art 
9137, E. Merck, Frankfurt, Germany. 
Spectra/Por equilibrium Dialyser 
Spectra/Por, SPECTRUM MEDICAL IND., INC, Los Angeles, 
California, U.S.A. 
St ir plate · 
NOOVA II SYBRON. Thermolyne, Dubuque, Iowa, U.S.A. 
183 
Tetramethylammonium Hydroxide solid 
Pentahydrate Formula wt 181.2, SIGMA Chemical Company 
st. Louis, Mo, U.S.A. 
Thymol crystals 
ClOH140 M=150. 22g/mol Extra pure, MERCK Art 8167, E. 
Merck, Frankfurt, Germany. 
Ultrasonic cleaner 
BRANSON Smi thKline, BRANSON CLEANING ~QT. Company, 
Woburn, MA, U.S.A. 
water bath 
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